Protocol  
 
Title : Automated Insulin Delivery for IN patients with DysG lycemia 
(AIDING) Feasibility Study   
 
Study ID: [REMOVED]  
 
 
Protocol Date: November 23, 2020 
 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
 
Signature Page  
Automated Insulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study   
IDE Sponsor: Francisco J. Pasquel , MD, MPH   
Version Number: 2.2 
23 NOV 2020 
 
Study supporter   Insulet Corporation  
Name, degree  Trang Ly, MBBS, FRACP, PhD  
Signature/Date   
 
Clinical Lead Investigator   
Name, degree  Francisco J Pasquel, MD, MPH  
Signature/Date   
 
Medical Monitor   
Name, degree  Roy W. Beck, MD, PhD  
Signature/Date   
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2  PAGE 2 OF 63 Automated Insulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study   
 
IDE Sponsor: Francisco J Pasquel, MD, MPH  
Funded by: Insulet Corporation  
 Version Number: 2.2 
23 NOV 2020 
 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2  PAGE 3 OF 63 KEY ROLES 
 
Principal Investigator, 
Coordinating Site   
Name, degree  Francisco J Pasquel, MD, MPH  
Title Assistant Professor  
Institution Name  Emory University School of Medicine  
 
Medical Monitor   
Name, degree  Roy W. Beck, MD, PhD  
Title Executive Director  
Institution Name  Jaeb Center for Health Research  
 
Study supporter   
Name, degree  Trang Ly, MBBS, FRACP, PhD  
Title SVP, Clinical and Medical Director  
Institution Name  Insulet Corporation  
 
Site Principal Investigator   
Name, degree  Bruce Buckingham, MD  
Title Professor  
Institution Name  Stanford University School of Medicine  
  
Site Principal Investigator   
Name, degree  Sue A. Brown, MD  
Title Associate Professor  
Institution Name  University of Virginia School of Medicine  
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 4 OF 63 TABLE OF CONTENTS  
CHAPTER 1: BACKGROUND INFORMATION  ......................................................................................... 15 
1.1 Introduction  .................................................................................................................................. 15 
1.2 Rationale  ...................................................................................................................................... 16 
1.2.1 Inpatient diabetes management and glycemic control targets  ................................................... 16 
1.2.2 Hybrid closed- loop insulin therapy  ......................................................................................... 18 
1.3 Preliminary Data  .......................................................................................................................... 22 
1.4 Potential Risks and Benefits of the [Investigational Device]  .......................................................... 25 
1.4.1 Known Potential Risks  ........................................................................................................... 25 
1.4.1.1 Hyperglycemia and Hypoglycemia Risks  ........................................................................ 25 
1.4.1.2 Other risks  ...................................................................................................................... 26 
1.4.2 Known Potential Benefits  ....................................................................................................... 26 
1.4.3 Risk Assessment  ..................................................................................................................... 26 
1.5 General Considerations  ................................................................................................................. 27 
CHAPTER 2: STUDY ENROLLMENT AND SCREENING  ........................................................................... 28 
2.1 Participant Recruitment and Enrollment  ........................................................................................ 28 
2.2 Informed Consent and Authorization Procedures  .......................................................................... 28 
2.3 Participant Eligibility .................................................................................................................... 29 
2.3.1 Inclusion Criteria  .................................................................................................................... 29 
2.3.2 Participant Exclusion Criteria  ................................................................................................. 29 
2.4 Screening Procedures  ................................................................................................................... 29 
2.5 Data Collection and Testing  .......................................................................................................... 30 
2.5.1 Daily data recording ............................................................................................................... 30 
CHAPTER 3: STUDY PROCEDURES  ....................................................................................................... 30 
3.1 Omnipod 5/Horizon automated insulin delivery system  ................................................................ 30 
3.1.1 Dexcom CGM validation  ........................................................................................................ 32 
3.1.2 Ongoing glucose monitoring  ................................................................................................... 33 
3.1.3 Insulin Delivery  ...................................................................................................................... 33 
3.2 Unit-based monitoring  .................................................................................................................. 34  
3.3 R
emote monitoring by research staff ............................................................................................. 34 
3.4 Interruption of HCL Therapy  ........................................................................................................ 35 
3.5 Discontinuation of HCL/AID  ........................................................................................................ 36 
CHAPTER 4: STUDY DEVICES ............................................................................................................... 37 
4.1 Description of the Investigational Device...................................................................................... 37 
4.1.1 Omnipod5/Horizonâ„¢ automated insulin delivery system  ........................................................ 39 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 5 OF 63 4.1.2 Continuous Glucose Monitoring  ............................................................................................. 40 
4.1.3 Horizon Data Portal  ................................................................................................................ 40 
4.1.4 Blood Glucose Meter and Strips  ............................................................................................. 40 
4.1.5 Study Device Accountability Procedures  ................................................................................ 41 
4.2 Safety Measures  ........................................................................................................................... 41 
4.2.1 CGM verification of validation  ............................................................................................... 41 
4.2.2 Pump Failure  .......................................................................................................................... 41 
4.2.3 Hypoglycemia Threshold Alarm and Safety Protocol  .............................................................. 41 
4.2.4 Hyperglycemia Threshold Alarm and Safety Protocol  ............................................................. 41 
CHAPTER 5: TESTING PROCEDURES AND QUESTIONNAIRES  ............................................................... 42 
5.1 Laboratory Testing  ....................................................................................................................... 42 
5.2 Surveys and Questionnaires  .......................................................................................................... 42 
CHAPTER 6: UNANTICIPATED PROBLEM, ADVERSE EVENT, AND DEVICE ISSUE REPORTING  ............ 43 
6.1 Unanticipated Problems  ................................................................................................................ 43 
6.2 Adverse Events  ............................................................................................................................ 43 
6.2.1 Definitions .............................................................................................................................. 43 
6.2.2 Reportable Adverse Events  ..................................................................................................... 44 
6.2.3 Hypogl ycemic Events  ............................................................................................................. 45 
6.2.4 Hyperglycemic/Ketotic Events ................................................................................................ 45 
6.2.5 Relationship of Adverse Event to Study Investigational Device  .............................................. 45 
6.2.6 Severity (Intensity) of Adverse Events  .................................................................................... 46 
6.2.7 Expectedness  .......................................................................................................................... 46 
6.2.8 Coding of Adverse Events  ...................................................................................................... 46 
6.2.9 Outcome of Adverse Events .................................................................................................... 47 
6.3 Reportable Device Issues  .............................................................................................................. 47 
6.4 Timing of Event Reporting  ........................................................................................................... 48 
6.5 Safety Oversight  ........................................................................................................................... 48 
6.6 Stopping Criteria  .......................................................................................................................... 49 
6.6.1 Participant Discontinuation of Study Device  ........................................................................... 49  
6.6.2
 Criteria for Suspending or Stopping Overall Study .................................................................. 50 
CHAPTER 7: MISCELLANEOUS CONSIDERATIONS  ............................................................................... 51 
7.1 Drugs Used as Part of the Protocol ................................................................................................ 51 
7.2 Collection of Medical Conditions and Medications  ....................................................................... 51 
7.3 Prohibited Medications, Devices, Treatments, and Procedures  ...................................................... 51 
7.4 Precautionary Medications, Treatments, and Procedures  ............................................................... 52 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 6 OF 63 7.5 Prophylactic Medications, Treatments, and Procedures  ................................................................. 52 
7.6 Rescue Medications, Treatments, and Procedures  ......................................................................... 52 
7.7 Pregnancy Reporting  .................................................................................................................... 52 
7.8 Participant Compensation  ............................................................................................................. 52 
7.9 Participant Withdrawal  ................................................................................................................. 52 
7.10 Confidentiality ............................................................................................................................ 52 
CHAPTER 8: STATISTICAL CONSIDERATIONS  ...................................................................................... 53 
8.1 Statistical and Analytical Plans  ..................................................................................................... 53 
8.2 Statistical Hypotheses  ................................................................................................................... 53 
8.3 Sample Size.................................................................................................................................. 53 
8.4 Outcome Measures  ....................................................................................................................... 53 
8.5 Analysis Dataset  ........................................................................................................................... 54 
8.6 Analysis of the Primary Efficacy Endpoint(s)  ............................................................................... 54 
The primary purpose of this pilot study is to assess the feasibility HCL use in the inpatient setting; 
therefore, no formal power calculations were performed. The main objectives of this study are to 
improve the quality and efficiency of the main study. In addition, it is conducted in order increase the investigatorsâ€™ experience with the technology in a different setting. We will list values for each patient 
as well as provide summary statistics appropriate to the distribution. To determine the operability of AID in the hospital (Aim 1) we will calculate the proportion of time spent in HCL after CGM sensor 
values meet validation criteria [sensor glucose values are within Â±20% of POC values for glucose levels 
â‰¥70 mg/dL or Â±20 mg/dL for POC glucose values <70 mg/dL]. To evaluate glycemic control (Aim 2) we will dete rmine the percentage of time sensor glucose values are within target glucose range [time- in-
range (TIR); 70 -180 mg/dL], during closed- loop insulin delivery.  ...................................................... 54 
8.7 Analysis of the Secondary Endpoints  ............................................................................................ 54 
8.8 Safety Analyses  ............................................................................................................................ 54 
8.9 Intervention Adherence  ................................................................................................................ 55 
8.10 Protocol Adherence and Retention  .............................................................................................. 55 
8.11 Baseline Descriptive Statistics  .................................................................................................... 55 
8.12 Device Issues .............................................................................................................................. 56 
8.13 Planned Interim Analyses  ........................................................................................................... 56 
8.14 Sub- Group Analyses  ................................................................................................................... 56 
8.15 Multiple Comparison/Multiplicity ............................................................................................... 56 
8.16 Exploratory Analyses  ................................................................................................................. 56 
8.17 Additional Tabulations and Analyses  .......................................................................................... 56 
C
HAPTER 9: DATA COLLECTION AND MONITORING  ........................................................................... 57 
9.1 Case Report Forms and Other Data Collection  .............................................................................. 57 
9.2 Study Records Retention  .............................................................................................................. 57 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 7 OF 63 9.3 Quality Assurance and Monitoring  ............................................................................................... 57 
9.4 Protocol Deviations  ...................................................................................................................... 58 
CHAPTER 10: ETHICS/PROTECTION OF HUMAN PARTICIPANTS  ......................................................... 59 
10.1 Ethical Standard ......................................................................................................................... 59 
10.2 Institutional Review Boards  ........................................................................................................ 59 
10.3 Informed Consent Process  .......................................................................................................... 59 
10.3.1 Consent Procedures and Documentation  ............................................................................... 59 
10.3.2 Participant and Data Confidentiality ...................................................................................... 59 
10.3.3 Future Use of Stored Specimens and Data  ............................................................................. 60 
CHAPTER 11: REFERENCES  .................................................................................................................. 61 
 
   
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 8 OF 63 LIST OF ABBREVIATIONS  
ABBREVIATION  DEFINITION  
ACE Alternate Controller Enabled  
ADE Adverse Device Effect  
AE Adverse Event  
AID Automated Insulin Delivery  
ARD Absolute Relative Difference  
BG Blood Glucose  
BMI Body Mass Index  
CEG Clarke Error Grid  
CGM Continuous Glucose Monitoring  
CI Confidence Interval  
COVID-19 Coronavirus -2019 
CRF Case Report Form  
CRP C-Reactive Protein  
CV Coefficient of Variation  
DIC Disseminated Intravascular Coagulation  
DKA Diabetic Ketoacidosis  
DM Diabetes Mellitus  
eGFR Estimated Glomerular Filtration Rate  
EGV Estimated Glucose Value  
EHR Electronic Health Record  
EKG Electrocardiogram  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
GV Glycemic Variability  
HbA1c Hemoglobin A1c  
HCW Healthcare Worker  
HDP Horizon Data Portal  
ICR Insulin-to-Carbohydrate Ratio  
ICU Intensive Care Unit  
IDE Investigational Device Exemption  
IL-6 Interleukin -6 
IRB Institutional Review Board  
ISF Insulin Sensitivity Factor  
IV Intravenous  
MARD Mean Absolute Relative Difference  
MPC Model Predictive Control  
PDM Personal Diabetes Manager  
POC Point-of-Care 
PPE Personal Protective Equipment  
PUI Person Under Investigation  
QA Quality Assurance  
QC Quality Control  
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 9 OF 63 ABBREVIATION  DEFINITION  
RBM Risk-Based Monitoring  
RCT Randomized Controlled/Clinical Trial  
SAE Severe Adverse Event  
SD Standard Deviation  
T1 Type 1 
T2 Type 2 
TAR Time Above Range  
TBI Total Basal Insulin  
TBR Time Below Range  
TDD Total Daily Dose  
TDI Total Daily Insulin  
TIR Time In Range  
UADE Unanticipated Adverse Device Effect  
 
 
 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 10 OF 63 SITE PRINCIPAL INVESTIGATOR STATEMENT OF COMPLIANCE  
Protocol Title: Automated Insulin Delivery for Inpatients with Dysglycemia (AIDING) 
Feasibility Study  
Protocol Version/Date: v. 2.2 / 11/23/2020  
I have read the protocol specified above.  In my formal capacity as a Site  Principal Investigator, 
my duties include ensuring the safety of the study participants enrolled under my supervision and 
providing the Sponsor with complete and timely information, as outlined in the protocol.  It is 
understood that all information perta ining to the study will be held strictly confidential and that 
this confidentiality requirement applies to all study staff at this site.  
This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as 
required by the following (use applicable regulations depending on study location and sponsor 
requirements; examples follow): United States (US) Code of Federal Regulations (CFR) 
applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 
312, and/or  21 CFR Part 812).  
For the foreign sites, the trial will be carried out in accordance with ICH E6 Good Clinical 
Practice (GCP), the Declaration of Helsinki, and specific regulations applicable to the countries in which the trial will be conducted.  
As the Principal Investigator, I will assure that no deviation from, or changes to the protocol 
will take place without prior agreement from the sponsor and documented approval from the 
Institutional Review Board (IRB), or other approved Ethics Committee, except w here necessary 
to eliminate an immediate hazard(s) to the trial participants.  
All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Participants Protection Training and Good Clinical Practice Training .  
Further, I agree to ensure that all staff members involved in the conduct of this study are 
informed about their obligations in meeting the above commitments.  
Investigatorâ€™s Signature __________________________________ D ate: _____ / _____ / _____ 
 dd mmm yyyy 
Investigatorâ€™s Name: ____________________________________ 
Site Name /Number: _____________________________________ 
 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 11 OF 63 PROTOCOL SUMMARY  
PARTICIPANT AREA  DESCRIPTION  
Title Automated Insulin Delivery for Inpatients with Dysglycemia (AIDING) 
Feasibility Study  
PrÃ©cis This single-arm stepwise feasibility study will test initial deployment of 
hybrid closed- loop (HCL) automated insulin delivery (AID) using the 
Omnipod 5/Horizon HCL system  with remote monitoring and device 
operation capabilities  to hospitalized patients  admitted to the general 
medical/surgical floor with diabetes (type 1 or type 2) requiring insulin 
therapy. All enrolled participants will be placed on HCL insulin therapy 
for 10 days or until hospital discharge  (if less than 10 days)  to 
determine  functiona l operability of the system and its effect on 
glycemic control in the hospital setting. This study will generate 
preliminary data to inform the design of a large multi -institution 
randomized controlled trial to assess superiority of HCL compared to 
standard inpatient insulin therapy . 
Investigational Device  The Omnipod  5/Horizon HCL system, consists of a disposable insulin 
infusion pump (or â€œpodâ€), a built -in model predictive control (MPC) 
insulin dosing algorithm, and a remote Personal Diabetes Manager (PDM) interface, that interact with a Dexcom G6 continuous glucose 
monitor (CGM) to automatically control insulin delivery based upon real-time glucose values. The PDM component also enables remote 
interaction with the system, including glucose monitoring as well as 
insulin dosing management and adjustments.  
Objectives  Primary objective:  
To investigate functional operability and implementation of the 
Omnipod 5/Horizon HCL system in the hospital setting.  
Secondary objectives:  
To describe glycemic control, device settings and insulin delivery 
parameters, and explore staff  and patient perceptions associated with 
early use of the Omnipod 5/Horizon HCL system in the hospital setting.  
Study Design  Pilot and Feasibility  
Number of Sites  3 
Endpoint  Primary Endpoint s: 
Aim 1 (Operability):  Proportion of time spent in HCL after CGM sensor 
meets initial validation  criteria [sensor glucose value  is within Â±20% of 
POC values (for glucose levels â‰¥70 mg/dL) or Â±20 mg/dL for POC 
glucose values <70 mg/dL].  
Aim 2 (Glycemic control):  Percentage of time sensor glucose is within 
target glucose range [time- in-range (TIR)], defined as 70- 180 mg/dL . 
Key Secondary Endpoints : 
Aim 1.1 Operability (System function) :  
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 12 OF 63 PARTICIPANT AREA  DESCRIPTION  
- Time from enrollment to start of HCL therapy (after in itial CGM 
validation ) 
- Percentage of time with CGM readings  
- Percentage of CGM values meeting accuracy criteria for 
bolus/correction insulin dosing 
- Number of CGM readings within %15/15 of POC readings and 
within %20/20 of POC readings with the cut point at 70 mg/dL 
Aim 1.2 Perception (qualitative analyses) : 
- Patient and Providers: Open- ended feedback  
- Patient and Providers:  Survey questionnaire results  
Aim 2.1. Glycemic control: 
- Number of hypoglycemic (<70 mg/dL) and clinically important  
hypoglycemic (<54 mg/dL) episodes per patient and per patient -
day 
- Percent time below range (TBR, <70mg/dL)  
- Percent time below range  (<54 mg/dL)  
- Percent time above range (TAR, >180 mg/dL) 
- Percent time in severe hyperglycemia (>250 mg/dL)  
- Coefficient of variation (CV), standard deviation (SD)  
Aim 2.2 HCL Settings : 
- Frequency of setting adjustments for clinically -important 
hypoglycemia (<54 mg/dL): Overall, to basal rate, to insulin 
carb ratio (ICR), to insulin sensitivity factor (ISF) 
- Frequency of setting adjustments for prolonged hyperglycemia 
(>250 mg/dL for >1 hour): Overall, to basal rate, to ICR, to ISF 
- Insulin requirements: Total daily insulin (TDI), Total daily basal 
insulin (TBI), Total daily bolus  (meal and correction) . 
Key Safety Outcomes:   
- Reportable hypoglycemia: defined as an event that required 
assistance of another person due to altered consciousness to 
actively administer carbohydrate, glucagon, or other 
resuscitative actions.  This means that the participant was 
impaired cognitively to the point that the participant was unable 
to treat his or herself, was unable to verbalize his or her needs, 
was incoherent, disoriented, and/or combative, or experienced 
seizure or coma.  
- Diabetic ketoacidosis  
 
Population  Key Inclusion Criteria:  
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 13 OF 63 PARTICIPANT AREA  DESCRIPTION  
- Patients â‰¥18 years of age with  insulin-treated T1 or T2DM 
admitted to general (non-intensive care) medical-surgical 
hospital service requiring inpatient insulin therapy.  
Key Exclusion Criteria:  
- Patients admitted the ICU or anticipated to require  ICU transfer  
- Anticipated length of hospital stay <48 hours.  
- Evidence of hyperglycemic crises (diabetic ketoacidosis or 
hyperosmolar hyperglycemic state)  at enrollment  
- Severely impaired renal function (eGFR < 30 ml/min/1.73m2) or 
clinically significant liver failure  
- Severe anemia with hemoglobin <7 g/dL  
- Evidence of hemodynamic instability  
- Hypoxia (SpO2 <95% on supplemental oxygen)  
- Pre-admission or inpatient total  daily insulin dose >100 units  
- Mental condition rendering the participant unable to consent or answer questionnaires  
- Pregnant or breast -feeding at time of enrollment  
- Unable or unwilling to use  rapid-acting insulin analogs 
(Humalog, Admelog, Novolog or Apidra ) during the study 
- Use of hydroxyurea or high- dose ascorbic acid  (>1g/day)  
-  COVID-19 infection or person under investigation (PUI) on 
isolation precautions   
Sample Size  18 patients  
Phase Pilot, Feasibility  
Treatment Groups  All enrolled participants will be placed on HCL insulin therapy for up to 
10 days or until hospital discharge . 
Participant Duration  Up to 10 days during inpatient stay  
 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 14 OF 63 OVERVIEW  OF STUDY DESIGN 
This multicenter study testing the feasibility of AID  (Omnipod 5/Horizon HCL system ) in the 
hospital will be conducted a cross three sites [Emory, Stanford, University of Virginia (UVA )]. 
To ensure safety of participants with this new impatient glycemic control approach we will 
employ a stepwise enrollment plan with two phases  (Figure 1). We will enroll patients â‰¥18 years 
of age with insulin-treated type 1 (T1) or type 2 (T2) DM  requiring insulin therapy during 
hospitalization  admitted to the general medical/surgical floor (non -ICU). To have 9 subjects in 
each phase cohort who have used the system for at least 48 hours, we will enroll up to a total of 
30 participants. All participant s will be placed on AID for inpatient glucose management.   
The first phase of the study will combine automated insulin delivery (AID) with intensified POC 
glucose monitoring (minimum of 6 POC glucose tests per day; n=9 subjects). During phase 2, 
AID will continue with less frequent POC glu cose monitoring ( approximately 4 times per day , 
standard-of-care; n=9  subjects) (Figure 1). IRB-approved informed consent will be obtained by 
study personnel designated at each site. Exclusion criteria include: 1) patients requiring total 
daily insulin dose >100 units,  2) patients admitted to  ICU, 3) patients anticipated to require <48  
hours of admission, 4) patients with evidence of hyperglycemic crises (diabetic ketoacidosis or 
hyperosmolar hyperglycemic state), 5) patients with severely impaired renal function (eGFR < 
30 ml/min/1.73m2), 6) clinically significant liver failure, 7) severe anemia (hemoglobin <7 g/dL), 
8) hypoxia (SpO2 <95% on supplemental oxygen) , 9) evidence of hemodynamic instability, 10) 
active or suspected COVID -19 infection, 11) a mental condition rendering the participant unable 
to consent or answer questionnaires, 12) pregnancy or breast feeding at time of enrollment , or 
13) use of hydroxyurea or high- dose ascorbic acid .  
 
 
Figure 1. AIDING Feasibility Study Stepwise Enrollment Design . IRB: Institutional Review Board; POC: point -of-care 
testing; AC: Before meals; HS: bedtime; MN: midnight.  
 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 15 OF 63 Chapter 1:  Background Information  1 
1.1 Introduction  2 
The purpose of this study is to assess the safety and efficacy of using the Omni pod 5/Horizon 3 
automated insulin delivery (AID) system in improving glycemic control for hospitalized patients 4 
requiring subcutaneous insulin therapy.  This is the first automated insulin delivery system which 5 
is well-suited for the hospital environment given its remote management capabilities with 6 
disposable components.  7 
The coronavirus disease 2019 ( COVID-19) pandemic has highlighted how accelerated use of 8 
technologies [ e.g., telemedicine, e- consults, and remote monitoring] has helped healthcare 9 
systems adapt care delivery  while minimizing exposure risk.  The pandemic has also shed light 10 
on the bedside care burden associ ated with inpatient diabetes management in its current state. As 11 
more patients are admitted with COVID -19 infection, there is continued concern surrounding 12 
resource limitations, including PPE. These concerns have led to transformations in clinical care 13 
that focus on the preservation of scarce resources while continuing to provide the highest level of 14 
clinical care. Inpatient diabetes (DM) management is one realm of clinical care that has seen 15 
major changes in the setting of COVID -19, mostly due to the time - and labor -intensive efforts 16 
required to care for hospitalized patients with DM.1 In the United States, it is estimated that 17 
about one in five patients with COVID -19 admitted to the hospital has DM.2 The increasing 18 
proportion of hospitalized patients with DM and concurrent COVID -19 infection continues to 19 
highlight the importance of advancing inpatient diabetes care to balance the competing demands 20 
of frequent glucose monitoring and timely insulin administration with the bedside contact 21 
required for these efforts when PPE is scarce.  22 
In Atlanta, a diagnosis of diabetes is associated with a threefold increase in the odds of 23 
hospitalizations.3 Among those patients with COVID -19 hospitalized in Georgia (primarily 24 
metropolitan Atlanta) beginning in February , DM was documented  in 39.7% of hospitalized with 25 
COVID-19,4 and a recent report showed about 46% of critically ill patients had DM in COVID 26 
units in the Emory healthcare system.5 Over 3500 cases of COVID -19 have been documented at 27 
Emory until the end of July 2020, including 883 patients with diabetes, of whom 114 expired 28 
(14%). At Stanford, of 2345 patients hospitalized with COVID -19 from March 1 to June 30, 29 
2020, 25% (580) had diabetes.  Among these 19% were intubated, and 2.6%  of these patients 30 
died. At UVA, a sample of 141 patients hospitalized with COVID -19 showed 52% required 31 
treatment with insulin.  We estimate at least 30% of patients with COVID -19 will have DM at 32 
the three centers.  33 
The use of AID systems continues to grow in the outpatient setting among patients with both 34 
type 1 and type 2 diabetes. Preliminary data from AID trials with a single non- commercial 35 
European system (using an insulin pump with tubing) has shown significant improvements in 36 
glycemic control in diverse populations, without increasing the risk of hypoglycemia .6-8 There is, 37 
however, no clinical trial data with the use of AID in the hospital in the US .  38 
$XWRPDWHG ,QVXOLQ'HOLYHU\IRU,1SDWLHQWVZLWK'\V*O\FHPLD$,' ,1*)HDVLELOLW\6WXG\
9(56,21 3 $*(2)7KH$,'V\VWHPFRQVLVWVRIWKH2PQLSRG+RUL]RQLQVXOLQLQIXVL RQSXPSRUÂ³SRGÂ´WKH+RUL]RQ 
3HUVRQDO'LDEHWHV0DQDJHU3'0DQGD'H[FRP*&*0 )LJXUH 7KHV\VWHPÂ¶V 
HPEHGGHGPRGHOSUHGLFWLYHFRQWURO03&DOJRULWKPXWLOL]HV&*0 JOXFRVHYDOXHVUDWHRI 
JOXFRVHFKDQJHDQGDFWLYHLQVXOLQIURPSUHYLRXVEROXVHVWRPDN HLQVXOLQGRVLQJGHFLVLRQV7KH 
DOJRULWKPKDVEHHQWHVWHGLQKXQGUHGVRISDWLHQWVUDQJLQJLQDJ HIURPWR\HDUVROGDQGKDV 
EHHQVWUHVVWHVWHGZLWKPLVVHGLQVXOLQEROXVHVIRU
PHDOVH[HUFLVHDQGLQVXOLQRYHUEROXVHVIRU
PHDOV7DEOH7KHSRGKROGVXQLWVRI 
LQVXOLQWKHHPEHGGHGDOJRULWKPDQGGLUHFWO\
UHFHLYHV%OXHWRRWKJOXFRVHYDOXHVIURPWKH*
VHQVRU7KH SRGLVZRUQIRUWKUHHGD\VDQGWKHQ 
GLVSRVHGWKHUHE\HOLPLQDWLQJWKHSRVVLELOLW\RI
FURVVFRQWDPLQDWLRQEHWZHHQSDWLHQWV7KH*
&*0VHQVRUODVWVGD\VZKLOHLWVWUDQVPLWWHU
ODVWVPRQWKV1HLWKHU&*0FRPSRQHQWVHQVRU
RUWUDQVPLWWHUZLOOEHUHXVHGEHWZHHQSDWLHQWV
7KHV\VWHPXVHVDGHGLFDWHGVPDUWSKRQH
>+RUL]RQ3HUVRQDO'LDEHWHV0DQDJHU3'0@WR
DOORZUHPRWHPRQLWRULQJYLDFHOOXODUGDWDDQG
:L)LQHWZRUNV,QVXOLQEROXVHVDQGDGMXVWPHQWV
WRSXPSVHWWLQJVFDQEHPDGHIURPWKH
VPDUWSKRQHLILWLVZLWKLQ%OXHWRRWKGLVWDQFHRI
WKHSRGDERXWIHHW:HKDYHWHVWHGWKLV
FRPPXQLFDWLRQZLWKLQWKHKRVSLWDOVHWWLQJDQGLWKDVZRUNHGZHO ODOORZLQJUHPRWHEROXVLQJDQG 
PRQLWRULQJIURPRXWVLGHRIDSDWLHQW
VURRPVHHSUHOLPLQDU\GD WD 
5DWLRQDOH
,QSDWLHQWGLDEHWHVPDQDJHPHQWDQGJO\FHPLFFRQWUROWDUJHWV 
,QWKH/HXYHQ6XUJLFDO7ULDO9D QGHQ%HUJKHHWDOUHSRUWHGLP SURYHPHQWLQPRUWDOLW\DQG 
PRUELGLW\LQDGXOW,&8SDWLHQWVXVLQJDJOXFRVHWDUJHWRI PJG/7KLVPRELOL]HGD 
GULYHWRVLJQLILFDQWO\UHGXFHLQSDWLHQWJOXFRVHOHYHOV+RZHYHU 1,&(68*$5DODUJH 
PXOWLFHQWHUUDQGRPL]HGFRQWUROOHGWULDODLPLQJWRUHSURGXFHWKR VHILQGLQJVLQVWHDGVKRZHGDQ 
LQFUHDVHLQGD\PRUWDOLW\LQ WKHLQWHQVLYHPDQDJHPHQWJURXS WDUJHWLQJHXJO\FHPLD7KHVH 
UHVXOWVZHUHODWHUDWWULEXWHGWRDQLQFUHDVHGUDWHRIPRGHUDWH WRVHYHUHK\SRJO\FHPLDVHHQDPRQJ 
WKHJURXSZLWKPRUHLQWHQVLYHJO\FHPLFWDUJHWVPJG/6XEVHTXHQWO\WREDODQFHWKH 
LPSRUWDQWEHQHILWVRIWUHDWLQJK\SH UJO\FHPLDDJDLQVWWKHLQFUHD VHGULVNRIK\SRJO\FHPLDLQ 
KRVSLWDOL]HGSDWLHQWVWKH$PHUL FDQ'LDEHWHV$VVRFLDWLRQ$'$ DQG$PHULFDQ$VVRFLDWLRQRI 
&OLQLFDO(QGRFULQRORJLVWV$$&(UHFRPPHQGHGDQLQSDWLHQWWDUJH WJOXFRVHUDQJHRI 
PJG/6LPLODUO\WKH6RFLHW\RI&ULWLFDO&DUH0HGLFLQH6&&0 DQGWKH(XURSHDQ6RFLHW\RI 
,QWHQVLYH&DUH0HGLFLQH(6,&0KDYHDOVRDGRSWHGDJOXFRVHJRD OÂ”PJG/LQWKHLU 
FROODERUDWLYH6XUYLYLQJ6HSVLV& DPSDLJQJXLGHOLQHVRQWKHPDQDJ HPHQWRIVHSVLVDQGVHSWLF 
VKRFN:KLOHWKHVHSDUDPHWHUVSURYLGHWKHFXUUHQWVWDQGDUGGLUH FWLQJLQSDWLHQWJOXFRVH 
PDQDJHPHQWJO\FHPLFYDULDELOLW\*9KDVDOVRJHQHUDWHGLQWHUH VWVLQFHVHYHUDOVWXGLHVKDYH 
VKRZQDQLQFUHDVHGULVNRIPRUWDOLW\LQGHSHQGHQWRIPHDQJOXFRV HOHYHOVDVVRFLDWHGZLWK 
LQFUHDVHG*9 
















+RUL]RQ
3HUVRQDO'LDEHWHV
0DQDJHU
3'0
)LJXUH2PQLSRG+RUL]RQ$,'V\VWHP
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 17 OF 63 Consideration has been made as to whether strict glucose control can improve outcomes 83 
specifically in hospitalized patients with COVID- 19. A multi -center retrospective analysis of 84 
7,337 patients with COVID -19 in Hubei Province, China18 reported an increased incidence of 85 
acute respiratory distress syndrome (ARDS), acute kidney injury, acute cardiac injury, 86 
disseminated intravascular coagulation (DIC), and all -cause in-hospital mortality among patients 87 
with pre-existing DM. As expected, these patients also had higher levels of acute inflammatory 88 
markers [C-reactive protein (CRP), procalcitonin, and D -dimer]. Yet, a sub -analysis of the cohort 89 
with DM revealed that in th ose with well- controlled glucose values (70-180 mg/dL) , these 90 
endpoints and laboratory findings were all significantly reduced.18 Similar findings were also 91 
reported by Sardu et al.19 in a 28-day prospective study to assess the effect of intensive glycemic 92 
control on progression to severe COVID -19 disease (ICU admission, mechanical ventilation, or 93 
death). In this study of 59 patients admitted with moderate COVID -19 pneumonia, two 94 
subgroups were characterized based on the admission glucose >140 mg/dL (hyperglycemic), or 95 
<140 mg/dL. Of the hyperglycemic patients, 72% had a diagnosis of DM prior to admission. All 96 
25 patients with hyperglycemia were asked to consent to intravenous (IV) insulin infusion if their 97 
glucose exceeded 180 mg/dL. Fifteen patients consented and were given IV insulin to target a 98 
glucose of 140- 180 mg/dL, while the other 10 patients received standard basal -bolus 99 
subcutaneous insulin injections. The mean glucose during hospitalization for those receiving IV 100 
insulin therapy was 138 Â± 33 mg/dL, and 192 Â± 15 mg/dL for those not receiving IV insulin. 101 
Hyperglycemia and higher baseline levels of interleukin 6 (IL -6) and D-dimer were associated 102 
with progression to severe disease. However, of those who opted for IV insulin, only 33% 103 
progressed to severe disease, compared to 80% of those who did not. Additionally, those 104 
receiving IV insulin demonstrated much larger reductions in IL -6 and D-dimer levels at one - and 105 
two-week time points. These early studies suggest that improved glucose control may promote 106 
better clinical outcomes among patients with COVID -19. 107 
However, use of continuous IV insulin infusion requires hourly interventions and significant 108 
oversight by healthcare providers. In non- ICU patients, basal -bolus insulin regimens continue to 109 
be the mainstay of therapy for patients with hyperglycemia in the hospital, relying heavily on the 110 
ability of healthcare workers ( HCW) to perform frequent blood glucose monitoring and timel y 111 
administration of multiple insulin injections to achieve glycemic control.20 During COVID -19, 112 
related shortages in PPE and the healthcare workforce will undoubtedly have a negative impact 113 
on inpatient glycemic control and outcomes for these patients. Additionally, inpatient 114 
hyperglycemia itself may become increasingl y challenging to mitigate, as rapidly evolving data 115 
has directed attention towards the use of high- dose steroids in the treatment of COVID -19.21 116 
Recent preliminary results from the â€œRandomised Evaluation of COVID -19 Therapyâ€ 117 
(RECOVERY) trial showed a significant reduction in 28-day mortality among patients requiring 118 
supplemental oxygen (including non- invasive ventilation) or invasive mechanical ventilation 119 
treated with high -dose dexamethasone (6 mg daily).22 Therefore, in light of the baseline 120 
prevalence and prognostic implications of pre -existing DM, early reports suggesting an 121 
association between glucose control and improved outcomes, and the now probable forthcoming 122 
increase in steroid usage among patients with COVID -19, maintaining glycemic control has 123 
become an integral part of inpatient COVID -19 management.  124 
Advances in diabetes technology have changed the face of diabetes care in the outpatient setting 125 
through the use of CGM, insulin pump therapy and the integration of these two technologies to 126 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 18 OF 63 provide AID.23 Recent efforts have focus ed on moving these technologies to the inpatient setting 127 
to improve hospital diabetes management.24 Our interest in this concept predates the pandemic, 128 
and we have previously reported our experience using CGM in the inpatient setting, including 129 
the implementation of a glucose telemetry sys tem ([STUDY_ID_REMOVED]).25-28 Recently, this progress 130 
has been accelerated and has become available for more widespread  clinical implementation  131 
during the COVID -19 pandemic. During the beginning of the pandemic, the US Food and Drug 132 
Administration (FDA) allowed for the use of CGM in the inpatient setting, with many hospitals 133 
rapidly implementing CGM with little guidance in a desperate effort to preserve PPE and glucose 134 
monitoring abillities.25,29 Already, this has shown some potential for the intended ancillary 135 
benefits, as one report of CGM with remote monitoring in four patients with COVID -19 in Israel 136 
showed a 50% decrease in the number of required bedside glucose measurements, as well as a 137 
decrease in the risk of staff exposure and care burden.30 The feasibility of remote real -time CGM 138 
use during COVID -19 was also recently reported by Reutrakul and colleagues.31 In addition, a  139 
reduction in hypoglycemia has also been demonstrated using inpatient remote real -time CGM in 140 
a recent trial at the Baltimore VA Medical Center.32 In this study, patients with T2DM on basal - 141 
bolus insulin who were considered at -risk for hypoglycemia were randomized to Dexcom G6 142 
CGM with data continuously available to nursing staff in a similar telemetry -like set-up vs. 143 
standard inpatient capillary BG checks (approximately four times daily) with a blinded CGM. 144 
Among those in the actively monitored CGM group, total per -patient glycemic  events <70mg/dL 145 
and <54 mg/dL were reduced by 60% (p=0.024) and 89% (p=0.003) respectively compared to 146 
standard of care. Reductions were also seen in percent of time spent below <70 mg/dL (0.40% 147 
vs. 1.88%, p=0.002) and below <54 mg/dL (0.05% vs. 0.82%, p= 0.017). Furthermore, a nother 148 
recent RCT using real -time CGM (G6) showed a  modest reduction of time spent in 149 
hyperglycemia >250 mg/dL ( -11.41%) with a similar approach but including alarms , the TIR 150 
(70-180 mg/dl) was 25% for the intervention group and 19.9%  in the control group.33 With a 151 
standard protocol using basal -bolus, the TIR (70- 180) was ~55% with two different basal 152 
insulins.27  153 
1.2.2 Hybrid closed -loop insulin therapy  154 
Hybrid closed- loop (HCL) or automated insulin delivery (AID) systems are one of the newest 155 
available technologies for diabetes management, designed to make algorithm -based adjustments 156 
to insulin infusion using CGM sensor glucose values and trends to maximize time in target 157 
glucose range [time in range (TIR), 70 -180 mg/dL]. An insulin delivery device (pump) interacts 158 
directly with the CGM to adjust insulin continuously according to need in real -time. The use of 159 
HCL therapy is being rapidly incorporated into ambulatory DM management and has been 160 
shown to be safe and effective in diverse populations and settings.34-37 The proposed 161 
Omnipod5/Horizon AID system, employing a personalized MPC algorithm, is a novel device 162 
that has been evaluated for safety in children and adults with T1DM, performing well under 163 
supervised free -living conditions.35 It has also been shown to cope effectively with common 164 
glycemic control challenges in  the outpatient setting, including daily physical activity and 165 
unrestricted meals in adults with T1DM.35,36 This system has demonstrated remarkable 166 
achievement of glycemic targets in children, adolescents, and adults with T1DM,35 including in 167 
those at the highest risk of hypoglycemia.36 For example, use of the Omnipod Horizon HCL 168 
system resulted in a very  low risk of hypoglycemia with a median of 0.9% Â± 1.3% of glucose 169 
readings <70 mg/dL and 0.09% Â± 0.25% <54 mg/dL in adults with T1DM treated as 170 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 19 OF 63 outpatients.38 They achieved 72.5% TIR (70- 180 mg/dL), a mean glucose of 154 Â± 15 mg/dL and 171 
a coefficient of variation (CV) of 30 Â± 6% .38  172 
The system provides a low rate of hypoglycemia with <2% of sensor glucose readings <70 173 
mg/dL, while achieving  over 70%  TIR.38 The pediatric subjects in the Omnipod 5 pivotal study 174 
entered the study with a mean glucose of 185 Â± 23 mg/dL with 51 Â± 13.3% TIR.38  Other initial 175 
trials of this AID system showed percentage of TIR above 70% in different age groups with 176 
various challenges applied to the AID system (Table 1) .  177 
 178 
While some recent efforts have been made to move these new technologies to the inpatient 179 
setting to improve hospital diabetes management,23,24 inpatient data for HCL /AID use is limited. 180 
Several studies from the United Kingdom have shown promising results in glycemic control 181 
parameters in specific hospitalized populations.6-8 For example, an inpatient trial by Bally et al. 182 
enrolling non- ICU patients with DM showed those assigned to closed- loop therapy achieved 183 
65% TIR compared to 41% with usual care (P<0.001) without an associ ated increase in 184 
hypoglycemia.6 Two recent studies reporting data on glycemic control using real -time CGM in 185 
the inpatient setting showed lower percent TIR achieved in this setting for patients on 186 
subcutaneous insulin regimens [median TIR 25.31% (11.78-42.97)33; mean TIR 56.6 Â± 25.6% 187 
and 57.5 Â± 25.1%27]. 188 
The Omnipod5/Horizon AID system has not been tested in hospitalized adults; however, among 189 
available options, we believe it is uniquely fashioned toward assimilation and optimal 190 
performance in the inpatient setting. The system provides significant hypoglycemia protection, 191 
with an automated â€œhypoglycemia protectâ€ feature which simultaneously raises the algorithmâ€™s 192 
glucose target to 150 mg/dL, decreases basal insulin delivery by 50%, and decreases the 193 Table 1. Initial studies of the Omnipod5/Horizon AID system.  
        
IDE G160169 G160169 G170012 G170012 G170143 Omnipod 5  Omnipod 5  
S003 S003 S001 S001 S002 Pivotal â€“ first 
4-9 weeks  Pivotal â€“ first 
4-9 weeks  
Age group  
(years) Adults Adolescents Adults Adults Adults Adults   
(14-70) Pediatrics  
(6-14) 
Challenge  100% 
meal bolus  100%  
meal bolus Meals Exercise Free-living Free-living Free-living 
Sample size (n)  10 12 12 12 11 18 18 
Study duration  36 hours 36 hours 54 hours 54 hours 96 hours 4-9 weeks 4-9 weeks 
Mean age (yrs)  41.7Â±18.1 14.6Â±1.5 35.4Â±14.2 36.6Â±14.4 28.3Â±7.5 35Â±11 10.6Â±1.8 
DM duration (yrs)  23.7Â±15.3  4.6Â±3.3 16.5Â±9.3 21.6Â±15.7  13.4Â±6.0 17Â±12 5Â±3 
A1C (%)  7.4Â±0.8 8.2Â±0.9 7.7Â±0.9 7.6Â±1.1 7.4Â±1.1 7.1Â±0.8 7.8Â±0.9 
Mean glucose  155.0Â±14.8  153.4Â±21.6  153.4Â±15.3  136.0Â±14.3  149.7Â±11.3  155 Â± 15 158 Â± 10 
Sensor Glucose (% 
time)        
70-180 mg/dL  73.0Â±15.0  72.6Â±15.5  76.1Â±8.0 85.1Â±9.3 73.7Â±7.5 73.8 Â± 9.1  70.1 Â± 5.2  
< 50 mg/dL  0.0 Â± 0.1 0.2 Â± 0.3 0.0 Â± 0.1 0.1 Â± 0.2 0.1Â±0.2 0.1 (0.0, 0.2)  0.2 (0.0, 0.5)  
< 70 mg/dL  0.7Â±1.2 2.0Â±2.4 0.6Â±0.9 1.4Â±1.3 1.9Â±1.3 0.9 (0.5, 1.3) 1.2 (0.9, 2.2)  
> 180 mg/dL  26.3Â±14.4  25.4Â±16.1  23.3Â±8.5 13.5Â±9.5 24.5Â±7.7 25.0 Â± 9.1  28.3 Â± 5.2  
â‰¥ 250 mg/dL  3.6Â±3.7 4.9Â±6.3 4.5Â±3.6 1.8Â±2.4 4.5Â±4.2 5.6 Â± 6.1 8.6 Â± 4.1 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 20 OF 63 aggressiveness of any insulin delivery in response to increasing glucose levels. G lucose rate of 194 
change information is also accounted for at the time of boluses, such that a reverse correction is 195 
calculated and instituted to prevent hypoglycemia when glucose levels are below the target at the 196 
time of a bolus insulin dose. As described previously, in the outpatient setting, these have 197 
resulted in extremely low rates of hypoglycemia ,38 and will be both practical and valuable in 198 
managing patients with variable insulin requirements . Automated features ar e supplemented by 199 
patient-specific physician input, as providers also have control over the insulin- to-carbohydrate 200 
ratios (ICR) and correction /sensitivity  factors (ISF) for manual dose calculations.  201 
Another key aspect of this system that makes it particularly attractive for inpatient use lies in its 202 
remote operation capability. Most HCL /AID insulin delivery systems require a physical 203 
connection between patient and device wherein the insulin pump is attached to the infusion site  204 
cannula by variable lengths of plastic tubing. However, the Omnipod is the only commercially 205 
available insulin pump that does not employ any tubing to connect the subcutaneous insulin 206 
infusion site to the insulin reservoir; both are contained within the disposable â€œPodâ€ worn by the 207 
patient. Additionally, the Omnipod 5/Horizon AID system employs a physically independent 208 
controller ( PDM smartphone) that is used to monitor CGM values and HCL functional status, 209 
perform infusion site  (pod) changes, and manually control insulin infusion when required 210 
(â€œopen-loopâ€ setting), while also allowing closed -loop/automated  insulin delivery to continue in 211 
the physical absence of the controller.35 This will enable HCW to interact with the pump, 212 
including delivering insulin and changing delivery settings from outside the patientâ€™s room. As 213 
such, this device independence offers a unique opportunity for insulin de livery in the 214 
hospital to improve glycemic control with remote management capabilities . 215 
A third key aspect of the Omnipod5/Horizon AID system is that all of the components are 216 
intended for single -person use  and have relatively low start -up costs compared to other available 217 
insulin pumps . The Omnipod5/Horizon AID system (PDM, pod) costs much less than other 218 
available closed -loop systems . Pumps used by the se other systems can cost on the order of 219 
$4,000 to $8,000 and are intended to be used for at least four years before replacement.  This 220 
makes it possible to use th e Omnipod5/Horizon AID system in the hospital without needing to 221 
own any component of the system  prior to admission , including the insulin pump (PDM).  This is 222 
especially relevant for patients requiring isolation.  223 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 21 OF 63 Our overarching central hypothesis  is that with the Omnipod 5/Horizon AID system, AID 224 
therapy is feasible and safe in the hospital, achieves superior glycemic control compared to the 225 
current standard of care, and reduces the frequency of patient -staff encounters associated with 226 
PPE use. This protocol is an initial implementation trial to assess feasibility of and barriers to 227 
larger-scale inpatient deployment of this system ( Aim 1) and to describe early experience with its 228 
use and glycemic control  in the hospital ( Aim 2). Results generated from this trial will serve as 229 
preliminary data in the creation of a large multi -institution randomized controlled trial (RCT) to 230 
assess superiority compared to standard of care insulin therapy, including the potential for future 231 
use in those with COVID -19 infection or other conditions requiring isolation precautions . 232 
Aim 1: To test the functional operability and applied use of the Omnipod 5/Horizon AID 233 
system in patients with DM admitted to the hospital  (Figure 3) . We will test deployment of 234 
the HCL system in each of the three institutions that plan to participate in the eventual RCT. 235 
Eighteen patients with pre -existing insulin-treated DM admitted to a non- ICU medical -surgical 236 
floor will receive HCL insulin therapy . Glucose monitoring will transition from intensified POC 237 
testing (phase 1, n=9) to standard of care POC testing (phase 2, n=9) . To investigate operability 238 
(Aim 1.1), we will specifically examine  the proportion of time spent in HCL  settings after initial 239 
CGM validation , percentage of time with CGM readings,  and percentage of bolus or corrective 240 
insulin doses given based on CGM values. We will also assess proportion of CGM values within 241 
Â±15 and 20% of POC reference values for glucose levels >70 mg/dL and Â±15 or 20 mg/dL for 242 
POC glucose levels â‰¤100 mg/dL (%15/15, %20/20 ). To assess perception and identify additional 243 
unforeseen barriers to implementation ( Aim 1.2), patients and hospital staff will be asked to 244 
Figure 3. Schematic for  Omnipod 5/Horizon AID  and Dexcom G6 CGM remote monitoring in the hospital.  
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 22 OF 63 provide intermittent open- ended feedback and structured surveys  regarding the use of the AID 245 
system. 246 
Hypothesis 1: Inpatient HCL therapy with the Omnipod 5/Horizon AID system functions 247 
well/consistently in the hospital and is supported by patients and staff . 248 
Aim 2: To assess glycemic control with the Omnipod 5/Horizon AID system in the inpatient 249 
setting. To describe glucometric data associated with inpatient HCL use ( Aim 2.1), we will 250 
analyze and report CGM data including percent time in target glucose range (TIR, 70-180 251 
mg/dL), number of hypoglycemic (<70 mg/dL) and clinically-important hypoglycemic (<54 252 
mg/dL) episodes per patient and per patient -day, percent time below range (TBR, <70mg/dL), 253 
percent time in clinically-important hypoglycemia range (<54 mg/dL), percent time above range 254 
(TAR, >180 mg/dL), percent time in severe hyperglycemia (>250 mg/dL), coefficient of 255 
variation (CV)  and standard deviation (SD). To assess HCL initiation settings and the need for 256 
setting adjustments in hospitalized patients  (Aim 2.2), we will evaluate the frequency of 257 
adjustments to insulin infusion doses including basal rate, insulin- to-carbohydrate ratio (ICR), 258 
and insulin sensitivity factor (ISF) in response to: 1) clinically -important hypoglycemia (<54 259 
mg/dL) and 2) prolonged hyperglycemia (>250 mg/dL for >1 hour).  260 
Hypothesis 2: The Omnipod 5/Horizon AID system is safe and provides adequate (>55% TIR)  261 
glycemic control in non-ICU hospitalized patients.  262 
This proposal addresses multiple unique opportunities for the transformation of inpatient 263 
diabetes care, including: the (1) translation of HCL /automated  insulin delivery to the inpatient 264 
setting, (2) the efficacy of these technologies in improving inpatient glycemic control and rates 265 
of iatrogenic hypoglycemia in patients admitted with DM and diverse admission diagnoses , and 266 
(3) the potential for future studies testing the  use of remote HCL and CGM technology for 267 
administration of insulin, as it pertains to  patients who have isolation precautions , including for 268 
COVID-19. 269 
1.3 Preliminary Dat a 270 
Our preliminary data from a  pooled analysis of inpatient CGM studies including 4,067 matched 271 
CGM and POC glucose values from non- ICU patients with T1 and T2DM showed an ove rall 272 
mean absolute relative difference ( MARD) of 12.8%. The MARD decreased with time as 273 
expected (12 hours: 16.4%, 24 hours: 14.4%, All values: 12.8%). The proportion of CGM values 274 
with in Â±15, 20 and 30% of POC reference values for glucose levels >100 mg/dL and Â±15, 20 or 275 
30 mg/dL for POC glucose levels â‰¤100 mg/dL (%15/15, %20/20, %30/30) increased between the 276 
first 12-hours (57.0, 69.2, 85.9%)  and 24- hours (63, 75.6, 89.2%) of sensor life. The overall 277 
proportion of  CGM 278 
values meeting %15/15, 279 
%20/20, %30/30 280 
criteria were 68.7, 81.7, 281 
93.8%, respectively 282 
(Table 2). MARD and 283 
median ARD varied 284 
according to categories 285 

Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 23 OF 63 of hemoglobin level and POC glucose level strata with minor variations according to renal 286 
function categories. The highest MARD was observed for patients with glucose levels in the 287 
hypoglycemic range (50-70mg/dL ; MARD 14.5% ) and for those with severe anemia 288 
(hemoglobin <7g/dL; MARD 17.8% ), Figure 4. 289 
A Clarke error grid (CEG) analysis of all matched pair data showed 98.7% of values falling in 290 
CEG Zones A+B (Zone A, 80.9%; Zone B, 17.8%; Zone C, 0.1%; Zone D, 1.1%, Zone E, 0.0%) , 291 
Figure 5. 292 
At Emory, for pat ients in the ICU with 293 
COVID-19, we have already begun using 294 
the Dexcom G6 CGM in conjunction 295 
with Glucommander -directed IV insulin 296 
therapy. Conceptually, this system 297 
parallels closely what we here propose to 298 
undertake with HCL therapy. Like HCL, 299 
Glucommander uses an algorithm to 300 
adjust insulin delivery based upon 301 
frequent glucose data input (every 1-2 302 
hours); however, in this case, insulin is 303 
provided intravenously, as is appropriate 304 
for critically ill patients. As such, beyond 305 
the CGM, the components of this system 306 
differ considerably from the Omnipod 307 
5/Horizon, which automates 308 
subcutaneous insulin delivery. In our 309 
Figure 5. Clark Error Grid analysis of inpatient CGM values  
compared to POC glucose testing (preliminary data, unpublished).  
Figure 4. MARD and median ARD comparing CGM with POC in non -ICU hospitalized patients  with diabetes, 
according to eGFR, glucose, and hemoglobin categories (preliminary data, unpublished).  
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 24 OF 63 early experience with the 310 
Dexcom G6/Glucommander 311 
system, we have observe d 312 
reliable adjustments  to IV 313 
insulin infusion based on the 314 
CGM values  using an 315 
intermittent validation protocol 316 
comparing CGM to POC 317 
glucose values to ensure 318 
ongoing CGM accuracy.  We 319 
have used a similar protocol for 320 
routine validation of CG M 321 
readings in the ICU  as we have 322 
proposed in this study. This 323 
involved creation of an 324 
embedded  glucose 325 
documentation and validation 326 
tool in the electronic health 327 
record (EHR) system (EPIC) 328 
itself, which after receiving the 329 
necessary POC glucose values, 330 
advises nursing staff on the 331 
necessary accuracy range in 332 
which the CGM glucose value 333 
must lie in comparison to the POC glucose entered (Â±20% for glucose values over 100 mg/dL) , 334 
Figure 6.  Criteria were also developed to ensure ongoing sensor reliability, with 335 
recommendations to revert back to POC glucose testing in cases of: 1) CGM sensor signal loss, 336 
2) loss of CGM trend arrow, and 3) rapid changes in sensor glucose values (>3 mg/dL/min). To 337 
investigate feasibility and reliability of the Omnipod 5/Horizon AID system in the inpatient 338 
setting, we assessed the ability of the pump (pod) and CGM devices to communicate with one 339 
another and with the Personal Diabetes Manager (PDM). The PDM is a dedicated android 340 
smartphone for the Omnipod5/ Horizon and Dexcom applications, which allows for remote 341 
control of the insulin pump and reception of CGM glucose values. R eliability of remote bolus 342 
insulin delivery and glucose monitoring in COVID -19-specific rooms was tested at Stanford and 343 
Emory.  The CGM was connected to a â€œwalk -aboutâ€ sensor simulator and  paired with the HCL 344 
pod. The CGM and pump (HCL pod) were separated from each other by 3- 4 feet to simulate 345 
placement on a patient. Because of current PPE sh ortages, and to avoid unnecessary personnel 346 
exposure risk on an active COVID -19 unit, only unoccupied rooms were tested. Communication 347 
was tested from the patient inside the room to the PDM stationed outside the room after closing 348 
room doors: (1) in different locations within the patient room (including bathroom); (2) with staff 349 
personnel acting as an intervening body; (3) in proximity to multiple activated patient care 350 
devices with interference potential (telemetry monitor, lights, TV, EKG, ultrasound, iPa d, IV 351 
pumps); and (4) with variable external PDM locations (wall, hall table). Throughout the testing, 352 
A 
B 
Figure 6. EHR documentation and validation. A) flowsheet shows upper and 
lower 20% range of POC to document validation (yes/no), B) remote EHR 
access to documented CGM values trend (green) and POC values.   
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 25 OF 63 and in every room for each configuration, CGM data remained continuous, with stable readings 353 
every five minutes. Each remote bolus was transmitted succes sfully. An 18-hour overnight test 354 
was also completed without any lapse in CGM data or HCL functionality  at Stanford . 355 
1.4 Potential Risks and Benefits  of the [Investigational Device]  356 
1.4.1 Known Potential Risks 357 
The protocol constitutes greater than minimal risk.   358 
1.4.1.1 Hyperglycemia and Hypoglycemia Risks  359 
The Hybrid Closed Loop System (Omnipod5/Horizon) will have a glucose target lower than 360 
what is in  the typical range  for target glucose  in most hospitals. As such, there may be greater 361 
risk for hypoglycemia.  However, wit h use of CGM and close monitoring by the study team and 362 
hospital staff, this risk should be small.  In outpatient studies of patients with T1DM using the 363 
Omnipod5/Horizon AID system, the median percent of glucose values  <70 mg/dL was 364 
<2%.  Hypoglycemia, if it occurs, could potentiate a cardiac arrhythmia. If hypoglycemia is 365 
severe enough a seizure, loss of consciousness, and even death is possible.  These are risks 366 
common to all people on insulin therapy.   367 
Hyperglycemia is a known risk with having diabetes, and can occur with rapid changes in diet, or 368 
the use of medications such as  glucocorticoids , or significant worsening of an underlying 369 
medical condition which can result in resistance to the effect of ins ulin on lowering glucose 370 
levels.  The pod only uses rapid- acting insulins, so if an insulin infusion catheter was dislodged 371 
or became kinked or the insulin flow was blocked, then there is an increased risk of developing 372 
hyperglycemia and with hours of interrupted insulin delivery this can lead to ketosis or diabetic 373 
ketoacidosis (DKA) which can lead to shock, coma, or death.  The glucose values will be 374 
monitored continuously and remotely by study staff, so prolonged hyperglycemia is unlikely to 375 
occur. 376 
Hypoglycemia and hyperglycemia could also result if there is over or under  delivery of insulin 377 
due to a device defect, failure or  malfunction of any of the components of the system including 378 
communication issues, or sensor issues.   379 
Although there is potential for harm from glucose management that is more intensive with a 380 
lower glucose goal than standard glucose management, the potential benefit exceeds the potential 381 
risk since outcomes of hospitalized diabetic individuals with uncontrolled dysglycemia  382 
frequently are poor.   383 
Once the study is completed, participants  will need to be transition ed from AID to a 384 
subcutaneous insulin regimen. The study team will have knowledge of insulin doses delivered by 385 
the Omnipod 5/Horizon AID system, which will be converted into a standard basal -bolus insulin 386 
regimen with  corrective insulin.  This transition to usual care could result in episodes of 387 
hypoglycemia  or hyperglycemia.  388 
We do not foresee any long- term risks from participating in this study.  389 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 26 OF 63 The study principal investigators at each site will be closely monitoring for hypoglycemia , 390 
hyperglycemia, and devic e function (errors or failures).  The site investigator will be notified 391 
when the amount of hypoglycemia exceeding a pre -specified threshold has occurred.   Any severe 392 
hypoglycemia, DKA, or unanticipated device issues will be reviewed by the Medical Monitor.     393 
1.4.1.2 Other risks  394 
Insertion of the pod infusion set catheter and/or the sensor wire can result in bruising, 395 
bleeding, redness, induration, infection, pain and discomfort.   The adhesives used to secure the 396 
pod and CGM sensor can cause local skin reactions, itching, redness, and allergic reactions to the 397 
adhesives.  398 
On rare occasions  the CGM sensor wir e may break off or be retained under the skin.   Rarely this 399 
could cause local redness, swelling, or pain at the insertion, and even require surgical removal.   400 
Blood draws as well as f ingersticks for blood glucose monitoring are part of routine care, but are 401 
also required by this study.   Blood draws and fingersticks may cause local pain, bruising and 402 
rarely can result in an infection  or fainting.  403 
Loss of confidentiality is a potential risk; howeve r, data are handled to minimize this risk. Data 404 
downloaded from the CGM and AID device will be collected for the study as measures of 405 
diabetes self -management behaviors. Some people may be uncomfortable with the researchers' 406 
having such detailed information about their daily diabetes habits  or with the questionnaires.  407 
1.4.2 Known Potential Benefits  408 
There are recognized benefits to simply being in a clinical study, including close clinical 409 
monitoring. The use of AID offers the prospect of direct benefit. As described above in this 410 
protocol, AID therapy is a Food and Drug Administration (FDA) approved therapy for T1D M in 411 
people 7-75 years of age with other AID systems. However, its efficacy in treating hospitalized 412 
patients with DM or inpatient hyperglycemia  is unknown.  At this time , it is not the standard of 413 
care for hospitalized patients.   414 
AID may benefit patients if  improved glucose control is achieved that reduces the incidence of 415 
adverse outcomes  due to infection or other conditions that lead to the need for 416 
hospitalization.   The information generated by the study will have  generalizable value to adults 417 
with insulin needs  who are hospitalized for serious illness es. If this therapy is well accepted by 418 
hospital personnel and hospital physicians, it could become the standard of care for patients with 419 
DM who are hospitalized  and require insulin therapy. The risk to pa tients is relatively small and 420 
the potential benefit is great if improved glucose control reduces the incidence of adverse 421 
hospital outcomes.  422 
1.4.3 Risk Assessment  423 
The risks for events such as DKA and severe hypoglycemia are no greater , and possibly less  424 
likely, with use of AID therapy compared with usual care not using a HCL system. The study 425 
offers the prospect of direct benefit, including the potential for improved glycemic control. Study 426 
team and nursing staff  will also be using CGM remote monitoring of their glucose values , which 427 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 27 OF 63 should reduce the risks of severe low blood glucose levels or prolonged high glucose levels.  In 428 
addition to monitoring,  the CGM validation procedures described in section 3.1 mitigate the risk 429 
of bolus or corrective insulin dosing based on an inaccurate CGM reading. Therefore, this 430 
protocol is consistent with the United Sta tes Department of Health and Human  Services, 431 
Protection of Human Subjects, Subpart D, section 46.405 (research involving greater  than 432 
minimal risk but presenting the prospect of direct benefit to the individual subjects  involved in 433 
the research).  434 
1.5 General Considerations  435 
The study is being conducted in compliance with the policies described in the study policies 436 
document, with the ethical principles that have their origin in the Declaration of Helsinki, with 437 
the protocol described herein, and with the standards of Good Clinical Practice (GCP).  438 
When feasible, data will be directly collected in electronic case report forms  (CRF), which will 439 
be considered the source data.  440 
The protocol is considered a significant risk device study, due to the fact that the use of the 441 
Omnipod5/Horizon AID system is experimental  and not approved for use in a hospital setting.  442 
The Dexcom G6 sensor is also not approved for use in a hospital setting.  Therefore, an 443 
investigational device exemption (IDE)  from the U.S. Food and Drug Administration (FDA) is 444 
required to conduct the study.  445 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 28 OF 63 Chapter 2:  Study Enrollment and Screening  446 
2.1 Participant Recruitment and Enrollment  447 
Enrollment will proceed with the goal of at least 18 patients completing the study. Up to 30 448 
patients may be enrolled to achieve this enrollment goal.   Study participants will be recruited 449 
from 3 clinical centers in the United States and  no clinical centers outside the United States .  All 450 
eligible participants will be included without regard to gender, race, or ethnicity.   451 
Potential study participants will be identified clinically from the hos pital service for people 452 
admitted with  insulin-treated DM (T1 or T2 ) requiring inpatient insulin therapy , and from 453 
consults sent to the endocrine service for hyperglycemia management. After a potential 454 
candidate for enrollment in the study is identified, their primary physician /inpatient team  will be 455 
contacted to see if they would like to have the patient approached about the study.  If so, one of 456 
the research staff, coordinator or research physician will explain the study to the patient to see if 457 
they are interested in participating.   458 
Participants : Eligible patients meeting inclusion and exclusion criteria as described below will 459 
be invited to participate during hospital admission. IRB -approved informed consent will be 460 
obtained by study personnel designated at each site  (Figure 1). 461 
ï‚§ Three sites will participate in this study (Emory, Stanford, UVA) . 462 
ï‚§ Eighteen patients will be included; up to 30 patients may be enrolled to achieve 463 
this enrollment target ( accounting for possible early hospital discharge, mortality and 464 
study withdrawal).  465 
ï‚§ Enrollment will proceed stepwise as below:  466 
ï‚§ Phase 1: Nine patients will receive AID (Omnipod 5/Horizon HCL with Dexcom 467 
G6 CGM) combined with intensified POC glucose monitoring (standard of care before 468 
meals and at bedtime, adding overnight glucose assessments at approximately 12AM and 469 
3AM, or approximately every 4 hours as clinically indicated ). 470 
ï‚§ Phase 2: Nine patients will receive AID combined with standard -of-care POC 471 
glucose monitoring (before meals and bedtime, or approximately every 6 hours as 472 
clinically indicated).  473 
2.2 Informed Consent and Aut horization Procedures  474 
Potential eligibility may be assessed as part of a routine -care examination.  Before completing 475 
any procedures or collecting any data that are not part of usual care, written informed consent 476 
will be obtained.   477 
For potential study par ticipants the study protocol will be discussed with study staff.  The 478 
potential study participant will be given the Informed Consent Form to read.  Potential study 479 
participants will be encouraged to discuss the study with family members and their personal 480 
physicians(s) before deciding whether to participate in the study.  481 
As part of the informed consent process, each participant will be asked to sign an authorization 482 
for release of personal information.  The investigator, or his or her designee, will review the 483 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 29 OF 63 study-specific information that will be collected and to whom that information will be disclosed.  484 
After speaking with the participant, questions will be answered about the details regarding 485 
authorization. 486 
A participant is considered enrolled when the informed consent form has been signed.  487 
2.3 Participant Eligibility  488 
2.3.1 Inclusion Criteria  489 
Individuals must meet all of  the following inclusion criteria in order to be eligible to participate 490 
in the study.  491 
ï‚§ Any patient â‰¥18 years of age with insulin-requiring T1 or T2DM  admitted to 492 
general (non-ICU) medical-surgical hospital service requiring  inpatient insulin therapy. 493 
2.3.2 Participant Exclusion Criteria  494 
Individuals meeting any of the following exclusion criteria at baseline will be excluded from 495 
study participation.  496 
ï‚§ Patients admitted to ICU   497 
ï‚§ Patients anticipated to require less than 48 hours admission  498 
ï‚§ Evidence of hyperglycemic crises (diabetic ketoacidosis or hyperosmolar 499 
hyperglycemic state)  500 
ï‚§ Severely impaired renal function (eGFR < 30 ml/min/1.73m2) or clinically 501 
significant liver failure  502 
ï‚§ Severe anemia with hemoglobin <7 g/dL  503 
ï‚§ Evidence of hemodynamic instability  504 
ï‚§ Hypoxia (SpO2 <95% on supplemental oxygen)  505 
ï‚§ Pre-admission or inpatient total- daily insulin dose >100 units daily  506 
ï‚§ Mental condition rendering the participant unable to consent or answer 507 
questionnaires 508 
ï‚§ Pregnant or breast -feeding at time of enrollment  509 
ï‚§ Unable or unwilling to use rapid- acting insulin analogs (Humalog, Admelog, 510 
Novolog or Apidra) during the study 511 
ï‚§ Use of hydroxyurea or high dose ascorbic acid (known interference with CGM 512 
system)  513 
ï‚§ COVID -19 infection or Person under investigation (PUI) on is olation precautions   514 
2.4 Screening Procedures  515 
After informed consent has been signed, a potential participant will be evaluated for study 516 
eligibility through the elicitation of a medical history, performance of a physical examination by 517 
study personnel and local laboratory testing (if needed) to screen for exclusionary medical 518 
conditions. 519 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 30 OF 63 2.5 Data Collection and Testing 520 
Admitting vital signs and height and weight measurements will be recorded.  A limited physical 521 
exam to assess the participantâ€™s skin and suitability for wearing the study devices will be 522 
performed by the study investigator or designee (a physician, resident/fellow, nurse practitioner 523 
or a physician assistant).  524 
The following procedures will be performed/data collected/eligibility cr iteria checked and 525 
documented: 526 
â€¢ Inclusion and exclusion criteria assessed  527 
â€¢ Demographics (date of birth, sex, race and ethnicity)  528 
â€¢ Contact information (retained at the site and not entered into study database)  529 
â€¢ Medical history  530 
â€¢ Substance use history (drinking, smoking, and drug habits)  531 
â€¢ Concomitant medications  532 
â€¢ Physical examination to include:  533 
ï‚¿ Weight, height  534 
ï‚¿ Vital signs including measurement of blood pressure and pulse  535 
â€¢ Blood glucose obtained at time of admission to the hospital if on insulin prior to 536 
admission, or blood glucose at the time insulin therapy was started in the hospital  537 
â€¢ Record latest O2 saturation  if one has been obtained 538 
â€¢ Order HbA1c if one has not been ordered  539 
â€¢ Order Creatinine if one has not been ordered 540 
â€¢ Urine or serum pregnancy test for all women who have reached menarche and are 541 
premenopausal and are not surgically sterile  542 
2.5.1 Daily data recording  543 
Each day the medications given will be recorded  in our database, with the time and dose of 544 
the medication.  The lowest O2 saturation , Hct, and highest creatinine will be recorded if they 545 
were obtained.  546 
The date and time of any laboratory measurements of serum glucose will be recorded into 547 
our database  548 
Chapter 3:  Study Procedures  549 
3.1 Omnipod 5/Horizon automated insulin delivery  system 550 
All participants will receive treatment with the Omnipod Horizon AID system with integrated 551 
Dexcom G6 CGM. These devices will communicate with a patient -specific Samsung  smartphone 552 
(the PDM) secured outside of the patient room and remotely monitored by nursing station and 553 
study team (see Figure 3). HCL therapy will continue until discharge or for 10 days from 554 
enrollment, whichever is shorter (see discontinuation below). Study procedures will be 555 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 31 OF 63 conducted in medical -surgical floors where study team has provided dedicated in- service 556 
training. 557 
Nursing staff in medical- surgical units  (AM and PM shifts)  will receive dedicated in -service 558 
training about the technology and the study protocol. Once a patient is identified by the study 559 
team, the nursing staff on the floor will be notified the patient will be on automated insulin 560 
delivery.  The nurse who will be working with the patient will receive an additional  review of 561 
study procedures and the devices being used.  Specific training will be focused on responding to 562 
sensor alerts,  and how to give a meal bolus and/or a correction insulin dose (using CGM vs POC 563 
glucose value).  The nursing staff will notify the research staff for any device alarms.  Study 564 
investigators will document enrollment of the patient in the EHR and provide nursing staff with 565 
24-hour contact information. The nurse will be instructed on how to respond to a hypoglycemic 566 
alarm, by obtaining a point of care meter glucose reading, and treating as per hospital standard of 567 
care if the meter BG is <80  mg/dL.   568 
 Specific topics that will be reviewed with the nurse taking care of the patient:  569 
1) How to give a bolus using the bolus calculator on the Horizon app using the 570 
CGM glucose or a meter BG reading if the CGM reading does not meet 571 
accuracy criteria. 572 
2) How the home screen appears when the subject is in open or closed-loop 573 
3) How to assess if the CGM is working properly, i.e. showing a glucose reading 574 
and trend. 575 
Research staff will initiate the system and  replace any components of the system requiring 576 
replacement during the study (pods or sensors).  Research staff will be notifying the nurse when 577 
there is hyperglycemia and the need for a correction dose.  578 
Patients will not interact with the AID system and will not be provided access to real- time CGM 579 
glucose dat a for self-monitoring.   Patients would not receive training or learn how to use the AID 580 
system for insulin delivery. The AID and CGM devices for control and monitoring will be 581 
secured in a locked container outside of the patient room to prevent unauthorized access to the 582 
system. Only trained personnel will be provided access.  The secured PDM will be placed within  583 
approximately 15 feet of the patient to minimize potential for signal loss. Should the PDM not b e 584 
communicating with the Pod/CGM, the research and nursing teams will receive an alert for 585 
signal loss >30 minutes to ensure communication is re -established.  586 
NOTE: communication with the PDM is not necessary to maintain closed -loop functionality, but 587 
is necessary for delivering bolus insulin and for remote system monitoring.  588 
Horizon app setup and AID initiation  (to be performed by research staff):  589 
â€¢ For safety, a unique identifier will be assigned to the patient and entered into the Horizon 590 
App.  591 
â€¢ Basic set up will be verified including correct  date and time. Two-person verification of 592 
pump settings for ICR, ISF, and basal rates will be individually customized and thereafter 593 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 32 OF 63 adjusted for each patient  by the study investigators using their clinical judgment. The target 594 
glucose will be set to 120 mg/dL  initially. The appropriat eness of these setting s will be 595 
reviewed every 24 hours by the research physicians at each site.   596 
â€¢ Initial basal rates will be determined using  either 60% of current total daily insulin 597 
dose (TDD) or 50% of weight -based TDD estimate if not on insulin prior to admission.   598 
â€¢ Pod application instructions : Fill a pod, clean skin, place pod, then activate pod.  Do 599 
not enter sensor transmitter ID until the sensor has been activated on the Dexcom app.  600 
â€¢ The pump can remain in manual mode.  A temporary basal rate may be required if the 601 
patient has long acting insulin on-board.  602 
â€¢ To determine where the Dexcom sensor will be inserted and where the pod will be 603 
inserted.  They should be â€œin line of sightâ€ of each other, and in areas where the patient is 604 
unlikely to be laying on them.  605 
â€¢ Dexcom G6 sensor will be inserted as per the user manual.  The transmitter ID will be 606 
recorded and entered in to the Dexcom app on the PDM.  The sensor will be inserted and 607 
activated using the sensor code.  The sensor code will be recorded in the sensor log.  Share 608 
function will be activated and the nursing station remote monitoring tablet will be invited  to 609 
follow, as well as the approved research team memb ers.  Sensor alerts will be set for a 610 
threshold of <80 mg/dL , and >250 mg/dL. 611 
â€¢ Once the sensor has been activated on the Dexcom app, the transmitter ID can be 612 
activated on the Horizon app.  Automated insulin delivery will not commence  until the 613 
Dexcom CGM accuracy is validated (see below) . 614 
â€¢ The PDM will be kept in a locked container outside of the patientâ€™s room, within 615 
approximately 15 feet of the patient.  616 
3.1.1 Dexcom CGM validation 617 
â€¢ All blood glucose values used to validate  the CGM sensor glucose values will 618 
result from  hospital point -of-care glucometer s. The type of glucometer used by the 619 
hospital will be documented in the study source documentation.  620 
â€¢ CGM validation should not be attempted  during times of rapid glucose 621 
fluctuations (indicated by one or more vertical CGM trend arrows). In this event, 622 
assessment will be attempted after stabilization of glucose, indicated by a single 623 
horizontal or angled CGM trend arrow.  624 
â€¢ Validation will be performed at the initiation of a new sensor/transmitter 625 
session and confirmed if the CGM sensor glucose value satisfies  the below criteria :  626 
o CGM glucose is within the range of 20% of BG for BG values â‰¥70 mg/dL  627 
[Validation range: ( BG x 0.8) to (BG x 1.2)] 628 
o CGM glucose is within the range of 20 mg/dL of BG for BG values <70 629 
mg/dL [Validation range: ( BG â€“ 20) to (BG + 20)] 630 
â€¢ Once validation is confirmed, the patient will be transitioned to HCL/ AID mode.  631 
â€¢ If validation criteria are not met within the first 12 hours of sensor wear , the CGM 632 
will be calibrated with the POC glucose value, and the system will remain in the 633 
manual/open-loop setting. Reassessment for CGM validation will occur every 2 to 8 634 
hours until criteria are met, or until an additional 12 to 24 hours has elapsed. If 12 to 24 635 
hours pass following calibration without a successful validation, a new sensor will be 636 
placed, and the process will be reattempted.  637 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 33 OF 63 â€¢ If a successful CGM validation is not achieved after 48 hours  despite th e above 638 
measures, the patient will instead be placed on standard insulin therapy under the care of 639 
the primary admitting service.  640 
3.1.2 Ongoing glucose monitoring  641 
POC glucose monitoring will be determined based on stepwise enrollment phase as below:  642 
Phase 1: POC glucose monitoring will occur at a minimum of 6x per day (below) as clinically 643 
appropriate 644 
- Before meals, at bedtime, approximately 12AM and 3AM  or  645 
- Approximately every 4 hours  646 
Phase 2:  Standard of care POC glucose monitoring with additional POC tests as clinically 647 
appropriate  648 
- Before meals and at bedtime  or 649 
- Approximately every 6 hours  650 
CGM values will be validated  as above and prior to any meal or correction insulin bolus . 651 
The CGM glucose value will be compared to a concurrent POC glucose value to verify device 652 
accuracy (validation criteria as above) . If validation  criteria are not met  by the CGM glucose 653 
value, the POC glucose value  will be used for bolus or correction insulin dose calculation by the 654 
HCL/AID system in lieu of th e CGM glucose value .  655 
At investigator discretion, or if >3 consecutive CGM values do not meet validation criteria 656 
during ongoing POC glucose monitoring after initial validation, calibration or sensor 657 
change will be performed.  658 
Insulin boluses will be given remotely by nursing staff or study team, but doses will be 659 
calculated by the HCL/AID system based on current CGM  or POC glucose information and 660 
carbohydrate content of meal or snack. Correction boluses will also be delivered as advised by 661 
the HCL/AID syste m. 662 
POC glucose assessments will be used instead of CGM sensor values in the setting of:  1) CGM 663 
signal loss for >1 hour, 2) loss of CGM trend arrow for >1 hour, and 3) any concerning clinical 664 
status changes. The pump will be transitioned to  manual/open-loop mode until the issue is 665 
corrected or the patientâ€™s clinical status is deemed appropriate by study investigators for 666 
transition back to HCL/AID mode.  667 
3.1.3 Insulin Delivery  668 
Nursing Training:  Nursing staff and hospital staff working with these patients will receive 669 
training on how the AID system works, and how to administer insulin boluses, and how to 670 
change an OmniPod5 pod (see competency checklist for health care professionals for using 671 
the AID system in appendix A).  672 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 34 OF 63 â€¢ Basal: Basal insulin delivery settings will be initiated and adjusted at the discretion of 673 
the study investigators.  Basal infusion rates will be dictated by the HCL algorithm when in 674 
automated (closed -loop) mode.  675 
â€¢ Prandial: Nursing staff will bolus prandial insulin calculated by the HCL /AID system 676 
from current validated CGM (or POC) glucose value  and meal size/carbohydrate content 677 
using the pre -set ICR. 678 
â€¢ Corrective:  Non-mealtime correctional boluses will be calculated by the HCL system 679 
(or determined by the pre -set ISF in open- loop settings), and will be given under the 680 
guidance of the research team.  681 
o NOTE: No CGM-based insulin dosing calculations will be made or administered if 682 
CGM validation is not completed and active.  683 
â€¢ Target Glucose:   The target glucose will initially be set at 120 mg/d L.  It is adjustable 684 
to targets between 110 to 150 mg/dL , and it can be programmed to have higher or lower 685 
targets at different times of the day.  The research staff will use their clinical judgement to 686 
modify the glucose targets for patient safety or to improve glycemic control.  687 
â€¢ HCL/Automated Mode:  in this mode, validated  CGM values are used by the device 688 
algorithm to automatically adjust insulin infusion rates to target glucose value of 120 mg/dL.  689 
â€¢ Open-loop/Manual Mode:  in this mode, insulin delivery depends only on preset basal 690 
rates, ICR, ISF and DIA; no CGM glucose data is required, but may be utilized for insulin 691 
dose decisions.   692 
3.2 Unit-based monitoring  693 
CGM data will be available to nursing staff at the nursing station on a dedicated tablet screen (or 694 
smartphone) and can also be viewed on the PDM stationed outside the patient room  in a locked 695 
container.  696 
â€¢ Nursing staff working with these patients will receiving training on using CGM 697 
data and will complete a competency checklist (Appendix A). 698 
â€¢ CGM alerts will be prog rammed at the nursing station (tablet) and on the PDM to 699 
alarm for glucose values <80 mg/dL. PDMs will be mobile, as they will need to move 700 
with the patient for any transfers.  701 
â€¢ For hypoglycemia alarms (CGM glucose <80 mg/dL), nursing staff will assess the 702 
patient and perform POC BG. If concurrent POC BG is <80 mg/dL, patient will be 703 
treated by institutional hypoglycemia protocol. If concurrent POC BG is >100 mg/dL, 704 
POC BG will be  reassessed in 1 hour. If CGM glucose remains in hypoglycemic range, 705 
but repeat POC BG remains discordant (>80 mg/dL), the study team will be contacted for 706 
further recommendations . 707 
â€¢ Battery on PDM will be assessed and charged at least daily.  708 
3.3 Remote monitori ng by research staff  709 
â€¢ The Dexcom Share app for research staff will be set to alarm for hypoglycemia as 710 
above, as well as for CGM glucose  values >250 mg/dL for >1 hour.  T he research staff 711 
will review patient glucose values, insulin delivery and patient stat us and determine if a 712 
corrective dose of insulin is indicated.   713 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 35 OF 63 â€¢ For unexplained hyperglycemic range CGM values (>300 mg/dL) exceeding 60 714 
minutes, POC glucose values will be obtained hourly for those with T1DM and every 2 715 
hours for those with T2DM to minimize the risk of hyperglycemic crises. If the CGM 716 
glucose remains above 300 mg/dL [>1 hour in T1DM or > 2 hours in T2D]   following a 717 
corrective insulin dose by the AID system , the study team will be alerted and additional 718 
correction action will be taken, with the nursing staff assessing the infusion site, changing 719 
the pod or initiating alternative insulin delivery methods (i. e. subcutaneous injections or 720 
IV insulin infusion) .   721 
â€¢ Ketones will be assessed at the discretion of the  study physician or primary 722 
hospital service for any  concern about possible ketosis or DKA by drawing a serum 723 
sample (beta- hydroxybutyrate) to be processed at the hospital laboratory.  724 
â€¢ Study team will be alerted if there are no CGM readings for 30 minutes and will 725 
contact the floor teams to assess the situation and reestabli sh communication.   726 
3.4 Interruption of HCL Therapy  727 
Imaging/Procedures:  if pump and CGM must be removed for any incompatible 728 
imaging/procedure (e.g. CT, MRI, surgery, electrocautery ), management will depend on length 729 
of required discontinuation:39-41 730 
ï‚§ Short: <1 hour  731 
BG 180-300: administer corrective bolus insulin  732 
If BG is >300: consider transition to IV insulin infusion or continued subcutaneous 733 
correction protoc ol 734 
ï‚§ Intermediate: 1 -3 hours 735 
BG 110-180: administer bolus insulin equal to 70% of the sum of basal rate over the 736 
prior 2-3 hours (do not administer if BG is <110).  737 
BG 180-300: administer corrective bolus insulin  738 
If BG is >300: consider transition to IV insulin infusion or continued subcutaneous 739 
correction protocol  740 
ï‚§ Long: >3 hours  741 
Consider transition to IV insulin infusion or continued subcutaneous insulin regimen 742 
within 1 hour of pump discontinuation and determine ability to transition back to 743 
HCL post -procedure. 744 
Surgical intervention:  patients will discontinue HCL insulin therapy and will be 745 
treated with subcutaneous or IV insulin as per hospital perioperative glycemic 746 
management protocol.  747 
ICU transfers:  patients requiring ICU transfer for any reason will be managed by ICU team 748 
for diabetes management (i.e. subcutaneous insulin or continuous intravenous insulin 749 
infusion). HCL/AID will be discontinued,  but use of the Dexcom CGM for glucose 750 
monitoring may be continued at ICU team discretio n. Upon transfer out of the ICU, patients 751 
may resume HCL therapy for diabetes management  when appropriate . Patients with 752 
worsening clinical condition (hypoxia or hemodynamically unstable) who do not meet ICU 753 
transfer criteria may resume the AID system once those conditions are under control.  754 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 36 OF 63 Emergency use of insulin for non-glucose- related indications: in the event that a pa tient requires 755 
insulin for a non-glucose- related indication , such as an IV insulin dose for the treatment of 756 
hyperkalemia, HCL therapy  should may be suspended temporarily  at the discretion of the 757 
investigator until confirmed resolution of the underlying condition (e.g. hyperkalemia resolves). 758 
If HCL therapy is suspended for >6 hours, the patient should be transitioned to and maintained 759 
on subcutaneous insulin until the underlying condition resolves and HCL the rapy can be 760 
resumed. 761 
3.5 Discontinuation of HCL/AID 762 
Criteria for discontinuation of HCL therapy for an individual participant , as well as study hold 763 
parameters are detailed below in sections 6.6.1 and 6.6.2.  764 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 37 OF 63 Chapter 4:  Study Devices 765 
4.1 Description of the Investigational Device  766 
The Omnipod5/Horizonâ„¢ System is composed of three primary components  (Figure 7):  767 
ï‚§ Omnipod5/Horizonâ„¢ Controller â€“ Horizon App (PDM) and Algorithm  768 
ï‚§ Omnipod5/Horizonâ„¢ Alternate Controller Enabled ( ACE) Pump â€“ Pod 769 
ï‚§ Dexcom G6  â€“ CGM  770 
The Omnipod5/Horizonâ„¢ System will provide automated insulin delivery when connected to a 771 
Dexcom G6 CGM. The system is expected to reduce hypoglycemia without incurring an 772 
unacceptable increase in hyperglycemia and mean glucose. The system is also expected to reduce 773 
the extent and magnitude of hyperglycemia associated with meals. Optimal post -prandial co ntrol 774 
requires the user to deliver meal boluses as in current â€œopen-loopâ€ therapy, but the normal 775 
operation of the control algorithm will be expected to compensate for mismatched meal boluses 776 
and prevent prolonged hyperglycemia. The system uses a control -to-target strategy that attempts 777 
to achieve and maintain a set target glucose level, with target setpoints at 110 mg/d L, 120 778 
mg/dL, 130 mg/dL , 140 mg/dL and 150 mg/dL . Target setpoints can be adjusted by the 779 
user/healthcare provider, and patterns of higher or lower setpoints at different times of the day 780 
can be programmed into the Horizon application.    781 
 782 
The Omnipod5/Horizonâ„¢ Controller is composed of two parts: the  Horizon application (â€œappâ€) 783 
and the model predictive control (MPC) algorithm on the Pod. The MPC algorithm provides 784 
insulin micro -boluses once every 5 minutes based upon the predicted glucose over a 60- minute 785 
prediction horizon. Optimal post -prandial cont rol will require meal boluses in the same manner 786 
as current pump therapy, but normal operation of the MPC algorithm will compensate for late or 787 
missed or underestimated meal boluses and mitigate prolonged hyperglycemia. The MPC 788 
algorithm uses the control-to- target strategy to achieve and maintain a set target glucose value, 789 
thereby reducing the duration of prolonged hyperglycemia and hypoglycemia. The MPC 790 
Figure 7. Components of the  Omnipod 5/Horizon AID  and Dexcom G6 CGM system.  
 
 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 38 OF 63 algorithm resides on the Pod (Pump) component of the Omnipod5/Horizonâ„¢ System (similar to 791 
the DASH alte rnate controller enabled (ACE)  pump cleared in K191679, as described further 792 
below).  793 
The Horizo nâ„¢ app will be the primary interface and will be used to start and stop a Pod, 794 
program basal and bolus calculator settings for manual m ode as well as program settings specific 795 
for Automated Mode (hybrid closed- loop).   796 
Manual (â€œOpen-loopâ€) Mode:  797 
In Manual Mode, the Omnipod5/Horizonâ„¢ System will function equivalently to the OmnipodÂ® 798 
DASH System, whic h was first cleared under K180045, most recently under K191679.  This 799 
includes delivering insulin at programmed basal rates and bolus amounts with the option to set 800 
temporary basal profiles. The Omnipod5/Horizonâ„¢ Controller will also have the ability to 801 
function as a sensor augmented pump in Manual Mode, using sensor glucose data provided by 802 
the CGM to populate the bolus calculator.  803 
Automated (â€œHybrid closed -loopâ€) Mode:  804 
In Automated Mode, the system will support the use of multiple target glucose values, currently 805 
intended to be 110- 150 mg/dL in 10 mg/dL increments. The research team will program basal 806 
rates, glucose targets and bolus calculator settings ( see section 3.2). These in turn will inform the 807 
MPC algorithm for insulin dosing parameters. The insulin dosing parameters will be adapted 808 
over time based on the total daily insulin (TDI) delivered during each Pod use. A temporary 809 
hypoglycemia protection mode (Hypo Protect) may be implemented by the user for various time 810 
durations during Automated Mode. With Hypo Protect, the algorithm reduces insulin delivery 811 
and is intended for use over temporary durations when insulin sensitivity is expected to be  812 
higher, such as with discontinuation of steroids, or a significant improvement in illness-related 813 
stress, and exercise for ambulatory patients . This function would be enabled at the discretion of 814 
the research physicians.   815 
The Omnipod5/Horizonâ„¢ System will include two apps on a locked- down smartphone (the 816 
Samsung J3), referred to as Personal Diabetes Manager (PD M): the Horizon App and the 817 
Dexcom App. This phone has shown good communication between the Pod and Dexcom G6 818 
sensor in the hospital setting, communicating from the hallway to far corners of the patientâ€™s 819 
room (including bathrooms), with multiple hospital monitoring devices and pumps functioning in 820 
the room. The Horizon App, which will have a similar interface to the cleared OmnipodÂ® DASH 821 
System (K191679), will allow the use of large text, graphics, and on- screen instructions to 822 
prompt the user through set -up processes. It will also be used to program the userâ€™s custom basal 823 
insulin delivery profile, check the Pod status, initiate bolus doses of  insulin, make changes to a 824 
patientâ€™s insulin delivery profile, handle system alerts and alarms, and enter Automated Mode.   825 
The Dexcom App interface is identical to the current app of the interoperable Dexcom G6 826 
Continuous Glucose Monitoring System (K191450) and will provide CGM data, alerts, and 827 
alarms to the user.   828 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 39 OF 63 The Horizon App and Dexcom App will not directly communicate with one another. Instead, the 829 
CGM transmitter will communicate estimated glucose values  (EGV) directly to the Pod. The 830 
Dexcom transmitter number must be entered into the Horizon App, and this information is sent 831 
to the Pod to allow transmission of EGV. The Pod will pair directly to the transmitter to receive 832 
EGV for the algorithm and also sends the EGV back to the Horizon App as shown in Figure 7. 833 
The Omnipod5/Horizonâ„¢ Controller provides the ability to calculate a suggested bolus dose 834 
through the use of the bolus calculator. The bolus calculator will have the option to use the EGV, 835 
which is communicated to the app via the Pod. If the sensor has passed validation criteria for the 836 
day, it is preferred that the EGV be used for correction and meal boluses, since the algorithm will 837 
also use the sensor rate of change information in calculating the insulin dose.  This allows for 838 
less insulin delivery when the estimated glucose is decreasing and more insulin delivery when 839 
the estimated glucose is increasing.  Insulin-on- board (IOB)  is calculated by the algorithm taking 840 
into account any manual bolus and insulin delivered by the algorithm.  841 
As with the cleared OmnipodÂ® DASH System, Insulet will utilize a proprietary encrypted 842 
security stack embedded within the Bluetooth Low Energy (BLE) communication. 843 
4.1.1 Omnipod5/Horizon â„¢ automat ed insulin delivery system  844 
The Pod component of the Omnipod5/ Horizonâ„¢ System is similar to the OmnipodÂ® DASH 845 
ACE Pump cleared under K191679. Compared to the DASH ACE Pump (K191679), the 846 
Horizonâ„¢ ACE Pump (Pod) has additional software to optimize communication to accept inputs 847 
from the CGM (Dexcom G6) and the Horizonâ„¢ Controller. The insulin delivery mechanism and 848 
the patient and fluid contacting components are identical to the DASH Pod.    849 
The Pod is a lightweight, self -adhesive device that the user fills with U -100 rapid- acting insulin 850 
and wears directly on their body. The Pod delivers insulin into the userâ€™s body through a small 851 
flexible tube, called a cannula, based on the commands from the compatible controller. In the 852 
Omnipod5/Horizonâ„¢ System, the Pod will house the MPC algorithm and com municate directly 853 
with the CGM and the Horizon App. The algorithm commands the Podâ€™s insulin delivery in the 854 
form of micro -boluses based on predicted glucose values. As with the cleared OmnipodÂ® DASH 855 
System, the Pod of the Omnipod5/ Horizonâ„¢ System will come pre -packaged in a sterile 856 
container with a fill needle and a fill syringe. Figure 8 below is a representation of the Pod.  The 857 
Omnipod5 has not been approved for commercial sale and has not been tested for use on 858 
hospitalized patients and is therefore considered experimental.  859 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 40 OF 63  860 
4.1.2 Continuous Glucose Monitori ng 861 
The second component of the Omnipod5/ Horizonâ„¢ System is the CGM. The 862 
Omnipod5/Horizonâ„¢ System will be interoperable with a compatible CGM, currently the 863 
Dexcom G6 CGM System (K191450). The Pod will communicate with the Dexcom G6 via 864 
Bluetooth Low Energy (BLE). Glucose values from the Dexcom transmitter will be sent to the 865 
MPC algorithm residing on the Pod and will be used in insulin dosing adjustments. The glucose 866 
values from the Dexcom transmitter will be sent independently to the Dexcom App on the 867 
controller. The Dexcom G6 sensor is not approved for use in a hospital setting and is  therefore 868 
considered experimental. Alarms will be set as described in sections 3.1.3 and 3.1.4. 869 
4.1.3 Horizon Data Portal 870 
Data are securely uploaded from the PDM to  the Insulet Cloud by cellular connection. Data are 871 
then transferred from Insulet Cloud to the Horizon Data Portal (HDP), which is a platform for 872 
data review and management. The HDP runs on an Amazon -based web server. The HDP will 873 
provide insights including but not limited to:  insulin delivery, time in range, time at each target 874 
BG, automated/manual mode comparisons, and time spent in each mode.  875 
The research investigators will have access to all uploaded data and be able to view historical 876 
trends.  877 
The Insulet Artificial Pancreas Remote Monitoring System (APRMS) allows remote monitoring 878 
of glucose  levels and insulin delivery in real -time, allowing remote evaluation of hospitalized 879 
patients by research staff.   880 
4.1.4 Blood Glucose Meter and Strips  881 
The point of care glucose meter approved by the hospital will be used for POC blood glucose 882 
readings. The meter undergoes quality control testing and the nurses are trained on its use. The 883 
specific meter used will vary by hospital . 884 
Figure 8:  The Pod of the Omnipod 5/Horizon â„¢ ACE pump  
 
 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 41 OF 63 4.1.5 Study Device Accountability Procedures  885 
Device accountability procedures will be detailed in the site procedures manual.  886 
4.2 Safety Measures  887 
4.2.1 CGM verification of validation  888 
Each new  study CGM will be validate d prior to use of AID. See section 3.1.1. 889 
4.2.2 Pump Failure  890 
In the event of an early pod failure, the research staff or nursing staff trained on pod filling and 891 
activation will initialize a new pod and remove the old pod. Pods will be disposed of in a 892 
biohazard waste container.  893 
4.2.3 Hypoglycemia Threshold Alarm and Safety Protocol  894 
The low glucose threshold alarm setting w ill initially be set to 80 mg/dL, this may  be adjusted by 895 
the research investigators as the study progresses, or for an individual patient, but will never be 896 
less than 70 mg/dL.   See sections 3.1.3 and 3.1.4. 897 
4.2.4 Hyperglycemia Threshold Alarm and Safety Protocol  898 
During the course of  the study and for individual patients , researchers will be permitted to 899 
change this setting within a range of 200 to 300 mg/dL .  Initially this alarm will be set to 250 900 
mg/dL. See sections 3.1.3 and 3.1.4. 901 
During the time period when the closed- loop syste m is operational and active, if a participantâ€™s 902 
CGM reading is >300 mg/dL for over 1 hour or â‰¥400 mg/dL at any point, the f ollowing steps  903 
will be taken : Ketones will be assessed at the discretion of the  study physician or primary 904 
hospital service for any  concern about possible ketosis or DKA by drawing a serum sample 905 
(beta-hydroxybutyrate) to be processed at the hospital laboratory.  906 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 42 OF 63 Chapter 5:  Testing Procedures and Questionnaires  907 
5.1 Laboratory Testing 908 
HbA1c: to be ordered after enrollment if not obtained within  one month prior to admission.    909 
Urine or serum pregnancy  test: to be ordered after enrollment  for all female enrollees  of 910 
childbearing potential.  911 
Additional biologic samples will not be collected or ordered expressly for the purpose of this 912 
study. However, certain lab results (i.e.  CBC, CRP, D -dimer, or IL-6 levels) obtained during the 913 
hospital admission  as part of the participantâ€™s medical care will be recorded in our data 914 
collection . 915 
5.2 Surveys and Questionnaires  916 
We will obtain feedback and suggestions from both the health care providers and the patients 917 
who are interacting with  the Omnipod5/Horizon HCL  system.  918 
At completion of the study, health care workers who used the system (e.g. hospitalists, nurses) 919 
will be asked to complete:   920 
â€¢ The 10-item System Usability questionnaire  (Appendix X)   921 
â€¢ A brief, 9-item questionnaire  (Appendix Y)  on their perceptions of using the system and 922 
their suggestions for future use of the system   923 
We acknowledge that  the inpatient providers will be  the primary interactive users with these 924 
devices and also that  hospitalized  patients may have varying degrees of illness, and therefore 925 
limited ability to participate  in questionnaires. However, we believe patient  input and 926 
feedback is also of great potential benefit. As such,  we have included patient surveys, but have 927 
limited them to 8-items, to be answered if  able.  928 
After patients are taken off the system  they will be asked to:   929 
â€¢ Fill out a brief, 8 -item questionnaire (Appendix Z) 930 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 43 OF 63 Chapter 6:  Unanticipated Problem, Adverse Event, and Device Issue  931 
Reporting  932 
6.1 Unanticipated Problems  933 
Site investigators will promptly report to  the study Principal Investigator and to the Medical 934 
Monitor all unanticipated problems meeting the criteria below within seven days. For this 935 
protocol, an unanticipated problem is an incident, experience, or outcome that meets all of the 936 
following criteria:  937 
ï‚§ Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures 938 
that are described in the protocol related documents, such as the IRB -approved research 939 
protocol and informed consent document; and (b) the characteristics of the subject 940 
population being studied. 941 
ï‚§ Related or possibly related to participation in the research (possibly related means there is 942 
a reasonable possibility that the incident, experience, or outcome may have been caused 943 
by the procedures involved in the resear ch) 944 
ï‚§ Suggests that the research places participants or others at a greater risk of harm than was 945 
previously known or recognized (including physical, psychological, economic, or social 946 
harm) 947 
These instances must be reported to the JCHR IRB within seven calendar days of recognition. 948 
The Director of the Human Research Protection Program will report to the appropriate regulatory 949 
authorities if the IRB determines that the event indeed meets the criteria of an Unanticipated 950 
Problem requiring additional reporting. 951 
6.2 Adverse Events  952 
6.2.1 Definitions  953 
Adverse Event (AE):  Any untoward medical occurrence in a study participant, irrespective of the 954 
relationship between the adverse event and the device(s) under investigation.  955 
Serious Adverse Event (SAE):  Any untoward medical occurrence that:  956 
ï‚§ Results in death.  957 
ï‚§ Is life-threatening; (a non- life-threatening event which, had it been more severe, 958 
might have become life -threatening, is not necessarily considered a serious adverse 959 
event). 960 
ï‚§ Requires prolongation of  current hospitalization.  961 
ï‚§ Results in persistent or significant disability/incapacity or substantial disruption of the 962 
ability to conduct normal life functions.  963 
ï‚§ Is considered a significant medical event by the investigator based on medical 964 
judgment (e.g., m ay jeopardize the participant or may require medical/surgical 965 
intervention to prevent one of the outcomes listed above).  966 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 44 OF 63 Unanticipated Adverse Device Effect (UADE):  Any serious adverse effect on health or safety or 967 
any life-threatening problem or death caused by, or associated with, a device, if that effect, 968 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 969 
investigational plan or application (including a supplementary plan or application), or any other 970 
unanticipated serious problem associated with a device that relates to the rights, safety, or 971 
welfare of participants ( 21 CFR 812.3(s) ). 972 
Adverse Device Effect (ADE):  Any untoward medical occurrence in a study participant which 973 
the device may have caused or to w hich the device may have contributed (Note that an Adverse 974 
Event Form is to be completed in addition to a Device Deficiency or Issue Form, unless excluded 975 
from reporting as defined in section 6.2). An event that occurs solely due to user error in which 976 
the device functions properly generally will not be considered an ADE unless it is determined 977 
that the instructions on the screen of the device or user manual (or similar training materials) 978 
may have contributed to the event (note: the event may still meet cr iteria for reporting as an 979 
adverse event).  980 
Device Complaints and Malfunctions:  A device complication or complaint is something that 981 
happens to a device or related to device performance, whereas an adverse event happens to a 982 
participant. A device complaint may occur independently from an AE, or along with an AE.  An 983 
AE may occur without a device complaint or there may be an AE related to a device complaint.  984 
A device malfunction is any failure of a device to meet its performance specifications or 985 
otherwise perform as intended. Performance specifications include all claims made in the 986 
labeling for the device.  The intended performance of a device refers to the intended use for 987 
which the device is labeled or marketed ( 21 CFR 803.3). Note: for reporting purposes, sites will 988 
not be asked to distinguish between device complaints and malfunct ions. 989 
6.2.2 Reportable Adverse Events  990 
For this protocol, a reportable adverse event includes any untoward medical occurrence that 991 
meets one of the following criteria:  992 
1. An ADE as defined in section  6.2.1, unless excluded from reporting in section 8.3 993 
2. An AE as defined in section 6.2.1 occurring in association with a study procedure  994 
3. An AE as defined in section 6.2.1 that affects the participantâ€™s ability to complete any 995 
study procedures  996 
4. Hypoglycemia meeting the definition of severe hypoglycemia as defined below  997 
5. Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, hyperglycemia 998 
or ketosis event meeting the criteria defined below.  999 
Hypoglycemia and hyperglycemia not meeting the criteria below will not be recorded as adverse 1000 
events unless associated with an Adverse Device Effect. Skin reactions from sensor placement 1001 
are only reportable if severe and/or required treatment.  1002 
All reportable AEsâ€”whether volunteered by the participant, discovered by study personnel 1003 
during questioning, or detected through physical examination, laboratory test, or other means â€” 1004 
will be reported on an AE form. Each AE form will be reviewed by the Medical Monitor  to 1005 
assess for safety and  study continuation . 1006 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 45 OF 63 6.2.3 Hypoglycemic Events  1007 
Hypoglycemia not associated with an Adverse Device Effect is only reportable as an Adverse 1008 
Event when either of the following parameters are met: 1009 
ï‚§ The episode is associated with acute severe cognitive impairment, including incoherence, 1010 
disorientation, and/or combativeness, seizure, or loss of consciousness. Note: If plasma 1011 
glucose measurements are not available during such an event, neurological recovery 1012 
attributable to the restoration of plasma glucose to normal is considered sufficient 1013 
evidence that the event was induced by a low plasma glucose concentration.  1014 
ï‚§ Capillary glucose is <40 mg/dL  1015 
When a hypoglycemic event meets the above reporting requirements, a Hypoglycemia Form 1016 
should be completed in addition to the Adverse Event Form.  Severe hypoglycemia events should 1017 
be considered to be serious adverse events with respect to reporting requirements.  1018 
6.2.4 Hyperglycemic/Ketotic  Events 1019 
Hyperglycemia not associated with an Adverse Device Effect is only reportable as an Adverse 1020 
Event if the event involved DKA . Hyperglycemic events are classified as DKA if the following 1021 
are present:  1022 
ï‚§ Symptoms such as polyuria, polydipsia, nausea, or vomiting;  1023 
ï‚§ Serum ketones >1.5 mmol/L or large/moderate urine ketones;  1024 
ï‚§ Either arterial blood pH <7.30, venous pH <7.24 , or serum bicarbonate  (or CO 2) <15 1025 
mEq/L 1026 
ï‚§ DKA is suspected as either the primary or a contributing cause for these findings  1027 
When a hyperglycemia/ke totic event meets the above reporting requirements, an Adverse 1028 
Event Form  should be completed. Events meeting DKA criteria should be considered 1029 
serious adverse events with respect to reporting requirements. Hyperglycemia events not 1030 
meeting criteria for DKA  generally will not be considered as serious adverse events 1031 
unless one of the SAE criteri a in section 6.2.1 is met. 1032 
6.2.5 Relationship of Adverse Event to Study Investigational Device 1033 
The study investigator will assess the relationship of any adverse event to be related or unrelated 1034 
by determining if there is a reasonable possibility that the adverse event may have been caused 1035 
by the study device.  1036 
To ensure consistency of adverse event causality assessments, investigators should apply the 1037 
following general guideline when determining whether an adverse event is related:  1038 
ï‚§ Unrelated : The AE is clearly not related to a study drug/device and a likely alternative 1039 
etiology exists such as an underlying disease, environmental or toxic factors or other therapy.  1040 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 46 OF 63 ï‚§ Unlikely Re lated: The AE does not follow a reasonable temporal sequence during or after 1041 
use of study drug/device and a more likely alternative etiology exists such as an underlying 1042 
disease, environmental or toxic factors, or other therapy.  1043 
ï‚§ Possibly Related : The AE o ccurred in a reasonable time during or after use of study 1044 
drug/device; but could be related to another factor such as an underlying disease, 1045 
environmental or toxic factors, or other therapy; and there is a possible, though weak, 1046 
scientific basis for establ ishing a causal association between the AE and the study 1047 
drug/device. 1048 
ï‚§ Probably Related:  The AE occurred in a reasonable time during or after use of study 1049 
drug/device; is unlikely to be related to another factor such as an underlying disease, 1050 
environmental or toxic factors, or other therapy; and there is a plausible, though not strong, 1051 
scientific basis for establishing a causal association between the AE and the study 1052 
drug/device.  1053 
ï‚§ Definitely Related : The AE occurred in a reasonable time during or after use of study 1054 
drug/device; cannot be explained by another factor such as an underlying disease, 1055 
environmental or toxic factors, or therapy; and there is a strong scientific basis for 1056 
establishing a causal association between the AE and the study drug/device.  1057 
ï‚§ Not Assessable : Causality of an adverse event cannot be judged because information is 1058 
insufficient or contradictory, and which cannot be supplemented or verified.  1059 
6.2.6 Severity ( Intensity ) of Adverse Events  1060 
The severity ( intensity) of an adverse event will be rated on a three-point scale: (1) mild, (2) 1061 
moderate, or (3) severe. A severity assessment is a clinical determination of the intensity of an 1062 
event. Thus, a severe adverse event is not necessarily serious. For example, itching for several 1063 
days may be rated as severe, but may not be clinically serious.  1064 
ï‚§ MILD: Usually transient, requires no special treatment, and does not interfere with the 1065 
participantâ€™s daily  activities.  1066 
ï‚§ MODERATE: Usually causes a low level of inconvenience, discomfort or concern to the 1067 
participant and may interfere with daily activities but is usually ameliorated by simple 1068 
therapeutic measures and participant is able to continue in study.  1069 
ï‚§ SEVERE: Interrupts a participantâ€™s usual daily activities, causes severe discomfort, may 1070 
cause discontinuation of study device, and generally requires systemic drug therapy or other 1071 
treatment.  1072 
6.2.7 Expectedness  1073 
For a serious adverse event that is considered possibly related to study device, the Medical 1074 
Monitor will classify the event as unexpected if the nature, severity, or frequency of the event is 1075 
not consistent with the risk information previously described in section 1.4 1076 
6.2.8 Coding of Adverse Events  1077 
The Medical Mo nitor will review the investigatorâ€™s assessment of causality and may agree or 1078 
disagree.  Both the investigatorâ€™s and Medical Monitorâ€™s assessments will be recorded.  The 1079 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 47 OF 63 Medical Monitor will have the final say in determining the causality  as well as whether an event 1080 
is classified as a serious adverse event and/or an unanticipated adverse device effect . 1081 
6.2.9 Outcome of Adverse Events  1082 
The outcome of each reportable adverse event will be classified by the investigator as follows:  1083 
ï‚§ RECOVERED/RESOLVED â€“ The participant recovered from the AE/SAE 1084 
without sequelae.  Record the AE/SAE stop date.  1085 
ï‚§ RECOVERED/RESOLVED WITH SEQUELAE â€“ The event persisted and had 1086 
stabilized without change in the event anticipated.  Record the AE/SAE stop date.  1087 
ï‚§ FATAL â€“ A fatal outcome is defined as the SAE that resulted in death.  Only the 1088 
event that was the cause of death should be reported as fatal.  AEs/SAEs that were 1089 
ongoing at the time of death; however, were not the cause of death, will be 1090 
recorded as â€œreso lvedâ€ at the time of death.  1091 
ï‚§ NOT RECOVERED/NOT RESOLVED (ONGOING) â€“ An ongoing AE/SAE is 1092 
defined as the event was ongoing with an undetermined outcome.  1093 
An ongoing outcome will require follow -up by the site in order to determine the 1094 
final outcome of the AE/S AE. 1095 
The outcome of an ongoing event at the time of death that was not the cause of 1096 
death, will be updated and recorded as â€œresolvedâ€ with the date of death recorded 1097 
as the stop date.  1098 
ï‚§ UNKNOWN â€“ An unknown outcome is defined as an inability to access the 1099 
participant or the participantâ€™s records to determine the outcome (for example, a 1100 
participant that was lost to follow -up). 1101 
If any reported adverse events are ongoing when a participant completes the study (or 1102 
withdraws), adverse events classified UADEs will b e followed until they are either resolved, or 1103 
have no prospect of improvement or change, even after the participant has completed all 1104 
applicable study visits/contacts. For all other adverse events, data collection will end at the time 1105 
the participant completes the study. Note: participants should continue to receive appropriate 1106 
medical care for an adverse event after their participation in the study ends.  1107 
6.3 Reportable Device Issues  1108 
All UADEs and ADEs as defined in section 6.2.1 will be reported on both a device issue form 1109 
and AE form, except for skin reactions from CGM sensor placement or pump infusion set 1110 
placement that do not require pharmacologic treatment.  As noted in section 6.2.1, events that 1111 
occur due to user error generally will not require completion of a device issue form.  1112 
Device complaints and device malfunctions will be reported except in the following 1113 
circumstances. These occurrences are expected and will not be reported on a Device Issue Form 1114 
assuming criteria for a UADE or ADE have not been met: 1115 
ï‚§ CGM sensor lasting fewer days than expected per manufacturer  1116 
ï‚§ CGM tape adherence issues  1117 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 48 OF 63 ï‚§ Battery lifespan deficiency due to inadequate charging or extensive wireless communication 1118 
ï‚§ Intermittent device component disconnections/communication failures not requiring system 1119 
replacement or workaround/resolution not specified in user guide/manual.  1120 
ï‚§ Device issues clearly addressed in the user guide manual that do not require additional 1121 
troubleshooting 1122 
6.4 Timing of Event Reporting  1123 
SAEs possibly related to a study device or study participation and UADEs must be reported to 1124 
the Coordinating Site (Emory University)  within 24 hours of the site becoming aware of the 1125 
event. This can occur via phone or email, or by  completion of the online serious adverse event 1126 
form and device issue form if applicable. If the form is not initially completed, it should be 1127 
competed as soon as possible after there is sufficient information to evaluate the event. All other 1128 
reportable ADEs and other report able AEs should be submitted by completion on the on- line 1129 
form within 7 days of the site becoming aware of the event.  1130 
The Coordinating Site will notify all participating investigators of any adverse event that is 1131 
serious, related, and unexpected. Notificat ion will be made within 10  working days after the 1132 
Coordinating Site becomes aware of the event.  1133 
Each principal investigator is responsible for reporting serious study- related adverse events and 1134 
abiding by any other reporting requirements specific to his/her Institutional Review Board or 1135 
Ethics Committee.  Where the JCHR IRB is the overseeing IRB, sites must report all serious, 1136 
related adverse events within seven calendar days.  1137 
Upon receipt of a qualifying event, the Sponsor will investigate the event to determine if a 1138 
UADE is confirmed, and if indicated, report the results of the investigation to all overseeing  1139 
IRBs, and the FDA within 10 working days of the Sponsor becoming aware of the UADE per 1140 
21CFR 812.46(b) (2).  The Medical Monitor must determine if the  UADE presents an 1141 
unreasonable risk to participants.  If so, the Medical Monitor must ensure that all investigations, 1142 
or parts of investigations presenting that risk, are terminated as soon as possible but no later than 1143 
5 working days after the Medical Monitor makes this determination and no later than 15 working 1144 
days after first receipt notice of the UADE.  1145 
Device malfunctions will be handled by the Sponsor or designee as described below.  In the case 1146 
of a device malfunction, information will be forwarded to Insulet by the study staff to be 1147 
addressed by approved company personnel.   1148 
6.5 Safety Oversight  1149 
The study Medical Monitor will review all adverse events and adverse device events that are 1150 
reported during the study.  Severe adverse events (SAE)  typically will be reviewed within 24 1151 
hours of reporting.  Other  AEs typically will be reviewed on a weekly basis. Additionally, the 1152 
Medical Monitor will review compiled safety data at the end of phase 1  (n=9) and phase 2  (n=9).  1153 
 1154 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 49 OF 63 Safety parameter review:  assessment for any of the below attributed to sensor error or 1155 
inappropriate insulin delivery by the AID syste m will be reviewed in aggregate after each phase.  1156 
ï‚§ Severe hypoglycemia is defined as severe if the event required assistance of another 1157 
person to actively administer carbohydrate, glucagon, or other resuscitative actions due to 1158 
altered consciousness.  1159 
ï‚§ UADE: means any serious adverse effect on health or safety or any life-threatening 1160 
problem or death caused by, or associated with, a device, if that effect, problem, or death 1161 
was not previously identified in nature, severity, or degree of incidence in the 1162 
investigational plan or application (including a supplementary plan or application), or any 1163 
other unanticipated serious problem associated with a device that relates to the rights, 1164 
safety, or welfare of subjects.  1165 
ï‚§ Diabetic Ketoacidosis (requires all four cr iteria to be met):  1166 
(1) Symptoms such as polyuria, polydipsia, nausea, or vomiting  1167 
(2) Serum ketones > 1.5 mmol/L or large/moderate urine ketones  1168 
(3) Either arterial blood pH < 7.30 or venous pH < 7.24 or serum bicarbonate < 15  1169 
(4) DKA is suspected as either the primary or a contributing cause for these findings  1170 
The Clinical Study Director will be informed of all cases of severe hypoglycemia and DKA 1171 
and the Medical Monitorâ€™s assessment of relationship to the study device; and informed of all 1172 
reported device issues. 1173 
6.6 Stopping Criteria  1174 
6.6.1 Participa nt Discontinu ation of Study Device  1175 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA 1176 
event (or a malfunction that could have led to severe hypoglycemia or DKA), use of the HCL 1177 
system will be suspended while the problem is diagnosed. The UADE will be reported to the 1178 
IRB and the FDA. After assessment of the problem and any correction, use of the system will not 1179 
be restarted until approval is received from the IRB  and the FDA. 1180 
HCL therapy will be discontinued and patients will be transitioned to standa rd subcutaneous 1181 
insulin therapy with continued management by the primary medical/surgical team or inpatient 1182 
endocrine consult service (as clinically warranted) if any of the  following occur: 1183 
ï‚§ The investigator believes it is unsafe for the participant to continue on the intervention.  1184 
This could be due to the development of a new medical condition or worsening of an 1185 
existing condition; or participant behavior contrary to the indications for use of the device 1186 
that imposes on the participantâ€™s safety 1187 
ï‚§ Participan tâ€™s clinical team feels transition to IV insulin infusion or MDI regimen is 1188 
necessary for glycemic control  1189 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 50 OF 63 ï‚§ A successful CGM validation has not been achieved per the protocol detailed in section 1190 
3.1.1 on two consecutive CGM sensors 1191 
ï‚§ The participant requests that the treatment be stopped  1192 
ï‚§ Participant pregnancy  1193 
ï‚§ Participant requires hemodialysis  or continuous renal replacement therapy (CRRT)  1194 
ï‚§ Participant requires treatment with hydroxyurea  or high dose ascorbic acid  1195 
ï‚§ One episode of DKA as defined in section 6.2.4 1196 
ï‚§ One episode of  severe hypoglycemia as defined in section 6.2.3 1197 
ï‚§ One episode of DKA as defined in section 6.2.4 and one severe hypoglycemia event as 1198 
defined in section 6.2.3 1199 
ï‚§ Participant is anticipated to be discharged from the hospital without plan to continue 1200 
HCL insulin therapy in outpatient setting; transition to subcutaneous insulin regimen will 1201 
be initiated pr ior to discharge.  1202 
Transfers to the ICU will prompt discontinuation of use of the HCL component of the system 1203 
(CGM may be used at described in section 3.2.1). However, p articipant may be transitioned back 1204 
to HCL therapy after transferring  out of the ICU to a non- ICU ward based on study team 1205 
assessment. ICU transfers will not be reported as AE or ADE unless the specific reason for 1206 
transfer is  glycemia-related (i.e. severe hypoglycemia or DKA).  1207 
6.6.2 Criteria for Suspending or Stopping Overall S tudy 1208 
In addition  to the suspension of device use due to a UADE as described in section 6.6.1, study 1209 
activities could be similarly suspended if the manufacturer of any constituent study device 1210 
requires stoppage of device use for safety reasons (e.g. product re call). The affected study 1211 
activities may resume if the underlying problem can be corrected by a protocol or system 1212 
modification that will not invalidate the results obtained prior to suspension.  1213 
Additionally, the entire study will be placed on hold pending further review and 1214 
recommendations by the Medical Monitor and  IRB for any of the following:  1215 
ï‚§ Adverse events attributable to study device (including DKA or seizure)  1216 
ï‚§ Two patients with â‰¥1 episode of severe hypoglycemia attributable to insulin delivered by 1217 
study device.  1218 
  1219 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 51 OF 63 Chapter 7:  Miscellaneous Considerations  1220 
7.1 Drugs Used as Part of the Protocol  1221 
Participants will be limited to the insulin approved for pump use (i.e. insulin lispro or insulin 1222 
aspart). 1223 
7.2 Collection of Medical Conditions and Medications  1224 
Pre-Existing Condition: Any medical condition that is either present at screening, a chronic 1225 
disease, or a prior condition that could impact the participantâ€™s health during the course of the 1226 
study (e.g., prior myocardial infarction or stroke).  1227 
Medical Conditions during the study:  In addition to conditions meeting the reporting 1228 
requirements for an adverse event or device issue as described above, the following medical 1229 
conditions should also be reported: (1) new diagnosis of a chronic disease (i.e., not present at the 1230 
time of enrollment), and (2) any medical condition that could affect the participantâ€™s ability to 1231 
carry out any aspect of the protocol or could affect an outcome assessment.  1232 
Medications: All medication for the treatment of  chronic pre -existing conditions, medical 1233 
conditions (including medical conditions that do not require recording) , and/or adverse events 1234 
that the participant is currently taking at screening and during the course of the study should be 1235 
recorded.  Nutraceuti cals and preventative treatment also should be recorded.  Medications only 1236 
taken as needed will only be recorded if used during the study (e.g. Glucagon for treatment of 1237 
severe hypoglycemia ). 1238 
7.3 Prohibited Medications, Devices, Treatments, and Procedures  1239 
Non-insulin antihyperglycemics:  non-insulin agents will be discontinued at enrollment   1240 
Additional insulins:  Treatment of hyperglycemia  with additional insulin beyond what is 1241 
delivered by HCL therapy will not be permitted in conjunction with ongoing HCL use. For  1242 
participants who require alternative or additional insulin therapy at the discretion of the patientâ€™s 1243 
inpatient providers, the HCL system will be discontinued, as described in section 6.6.1. 1244 
Emergency use on insulins for non-glucose- related indications , such as hyperkalemia, are 1245 
permitted; however, HCL therapy may be temporarily suspended at the discretion of the 1246 
investigator and subsequently resumed as described in section 3.2.1. 1247 
Hydroxyurea:  Participants who require treatment with hydroxyurea will discontinue HCL 1248 
therapy, as described in section 6.6.1. 1249 
High-dose ascorbic acid (>1g/day) : Participants who require treatment with ascorbic acid  will 1250 
discontinue HCL therapy, as described in section 6.6.1. 1251 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 52 OF 63 All study devices (insulin pump, CGM) must  be removed before Magnetic Resonance Imaging 1252 
(MRI) or diathermy treatment. CGM equipment may be worn during Computed Tomography 1253 
(CT).  1254 
7.4 Precautionary Medications, Treatments, and Procedures  1255 
Acetaminophen doses of >1 gram every 6 hours may cause CGM readings to be artificially 1256 
elevated. Acetaminophen use should be limited to â‰¤4 grams per day. 1257 
7.5 Prophylactic Medications, Treatments, and Procedures  1258 
This section is not applicable to this study.  1259 
7.6 Rescue Medications, Treatments, and Procedures  1260 
All rescue ther apies are allowed at the discretion of the participantâ€™s inpatient providers. HCL 1261 
therapy should be discontinued in the event that certain medications are required, as described in 1262 
sections 3.2.1, 6.6.1 , and 7.3. 1263 
7.7 Pregnancy Reporting  1264 
Pregnancy occurring during this study is highly unlikely. However, if pregnancy is discovered 1265 
after enrollment , the participant will be discontinued from the study. The occurrence of 1266 
pregnancy will be reported to the Coordinating Site within seven days and to the JCHR IRB as 1267 
an Unanticipated Problem  within seven calendar  days.  1268 
7.8 Participant Compensation  1269 
Participant compensation will be specified in the informed consent form.  1270 
7.9 Participant Withdrawal  1271 
Participation in the study is voluntary, and a participant may withdraw at any time. For 1272 
participants who withdraw, their data will be used up until the time of withdrawal.  1273 
7.10 Confidentiality  1274 
For security and confidentiality purposes, participants will be assigned an identifier that will be 1275 
used instead of their name. Protected health information gathered for this study will be shared 1276 
with the Statistical C enter, the Jaeb Center for Health Research in Tampa, FL. De- identified 1277 
participant information may also be provided to research sites involved in the study.1278 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 53 OF 63 Chapter 8:  Statistical Con sideration s 1279 
8.1 Statistical and Analytical Plans  1280 
The approach to sample size and statistical analyses are summarized below.   1281 
8.2 Statistical Hypotheses  1282 
This is a pilot and feasibility trial and is not powered to reach statistical conclusions.  1283 
8.3 Sample Size  1284 
The sample size was a convenient sample size by which to obtain preliminary data on 1285 
implementing the HCL/AID system in a hospital setting. The maximum number of participants 1286 
to be consented for participation in  this study (n= 30) is based upon the goal of enrolling 18 1287 
patients with at least 48 hours of data during HCL therapy and to account for  the potential for 1288 
early device wear termination, ICU transfer , or early discharge.  1289 
8.4 Outcome Measures 1290 
Primary Endpoints:  1291 
Aim 1: Proportion of time spent i n HCL after CGM validation  1292 
Aim 2: Percentage of time sensor glucose is within target glucose range [time -in-range (TIR)], 1293 
defined as sensor glucose 70-180 mg/dL.  1294 
Secondary Endpoints : 1295 
Aim 1.1: System function  1296 
ï‚§ Time from enrollment to start of HCL therapy  1297 
ï‚§ Percent of time with CGM readings  1298 
ï‚§ Percentage of validations that were successful  1299 
ï‚§ Number of CGM readings within %15/15 of POC readings and within %20/20 of 1300 
POC readings with the cut  point at 70 mg/dL .   1301 
 1302 
Aim 1.2: Implementation processes and adoptability of inpatient HCL therapy by clinical staff 1303 
and patients (Qualitative analyses)  1304 
ï‚§ Patient and Providers : Open-ended feedback  1305 
ï‚§ Patient and Providers : Survey questionnaire results  1306 
Aim 2.1: Glycemic control  1307 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 54 OF 63 ï‚§   Number of hypoglycemic (<70 mg/dL) and clinically-important hypoglycemic (<54 1308 
mg/dL) episodes per patient and per patient -day 1309 
ï‚§ Percent time below range (TBR, <70mg/dL) 1310 
ï‚§ Percent time in clinically -important hypoglycema (<54 mg/dL)  1311 
ï‚§ Percent time above range (TAR, >180 mg/dL)  1312 
ï‚§ Percent time in severe hyperglycemia (>250 mg/dL)  1313 
ï‚§ Glycemic variability (CV and SD) 1314 
Aim 2.2: HCL Settings  1315 
ï‚§ Frequency of setting adjustments for clinically -important hypoglycemia (<54 1316 
mg/dL): Overall, to basal rate, to ICR, to ISF  1317 
ï‚§ Frequency of setting adjustments for prolonged severe hyperglycemia (>250 1318 
mg/dL for >1 hour), Overall, to basal rate, to ICR, to ISF 1319 
ï‚§ Insulin requirement s: Total daily insulin (TDI), Total daily basal insulin, Total 1320 
daily bolus  insulin 1321 
8.5 Analysis Dataset  1322 
All relevant participant data will be included in the analysis of a single data set for this feasibility 1323 
study. 1324 
8.6 Analysis of the Primary Efficacy Endpoint(s)  1325 
The primary purpose of this pilot study  is to assess the feasibility HC L use in the inpatient 1326 
setting; therefore,  no formal power calculations we re performed. The main objectives of this 1327 
study are to improve the quality and efficiency of the main study. In addition, it is conducted in 1328 
order increase the investigatorsâ€™ experience with the technology in a different setting. We will 1329 
list values for each patient as well as provide summary statistics appropriate to the distribution. 1330 
To determine the operability of AID in the hospital (Aim 1) we will calculate the proportion of 1331 
time spent in HCL after CGM sensor values meet validation criteria [sensor glucose values are 1332 
within Â±20% of POC values for glucose levels â‰¥70 mg/dL or Â±20 mg/dL for POC glucose values 1333 
<70 mg/dL]. To evaluate glycemic control (A im 2) we will determine the percentage of time 1334 
sensor glucose values are within target glucose range [time -in-range (TIR ); 70-180 mg/dL ], 1335 
during closed-loop insulin delivery. 1336 
8.7 Analysis of the Secondary Endpoint s 1337 
The analysis of secondary endpoints will parallel that described above for the primary analysis 1338 
with summary statistics given for each of the metrics listed in Section 8.4  1339 
8.8 Safety Analyses  1340 
Safety endpoints will be analyzed using summary statistics during trea tment. AEs will be coded 1341 
as described in section  6.2.8. Severity and relationshi p of AE to study agent will be determined 1342 
as described in section 6.2. The event start date, stop date, severity, relationship, outcome, and 1343 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 55 OF 63 duration will also be recorded. The Medical Monitor will conduct a review of safety parameters 1344 
at the end of each study phase, as described in Section 6.5.  1345 
The following will be tabulated during the feasibility study: 1346 
â€¢ Number of adverse events  1347 
â€¢ Number of participants with at least one event  1348 
â€¢ Number of serious adverse events  1349 
â€¢ Number of participants with at least one serious adverse event  1350 
â€¢ Number of unexpected device events  1351 
â€¢ Number of unexpected serious device events  1352 
â€¢ Number of ICU transfers  1353 
â€¢ Number of adverse events thought by investigator to be related to study device  1354 
â€¢ Number of participants who stopped the intervention in response to an adverse 1355 
event 1356 
â€¢ Number of severe hypoglycemic events as defined in the protocol  1357 
â€¢ Number of severe hypoglycemic events associated with seizure or loss of 1358 
consciousness 1359 
â€¢ Number of diabetic ketoacidosis events as defined in the protocol  1360 
8.9 Intervention Adherence 1361 
The adherence to the protocol will be determine d by daily use of HCL after enrollment  and will 1362 
be calculated from t ime of enrollment to ICU transfer or hospital dischar ge. We will obtain 1363 
preliminary estimates about the frequency and reasons for discontinuation of the intervention 1364 
during this feasibility study.  1365 
8.10 Protocol Adherence and Retention  1366 
Potential study subjects will be identified and pre -screened among non-ICU patients with 1367 
hyperglycemia requiring insulin therapy. Strategies to address potential problems with 1368 
recruitment will include bi-weekly communications with Drs. Pasquel, Davis, Bucki ngham, Lal, 1369 
and Brown.  1370 
A study coordinator or investigator will conduct informed consent in eligible subjects prior to 1371 
any study procedures. Screening and recruitment reports will be generated monthly that include 1372 
actual and expected recruitment statistics . Based on preliminary studies with inpatient use of 1373 
CGM we expect to retain most patients in this study.  1374 
8.11 Baseline Descriptive Statistics  1375 
Baseline characteristics will be collected and reported for all participants in this feasibility study.  1376 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 56 OF 63 8.12 Device Issue s 1377 
Any technical issues will be reported to Insulet Corporation. Any device issues affecting patient 1378 
care will be reported as below and reviewed by the Medical Monitor.   1379 
8.13 Planned Interim Analyses  1380 
The criteria below will be considered events prompting an inte rim review and safety analysis 1381 
prior to continuation of the study. The study investigators and statisticians will perform the 1382 
statistical analysis that will be reviewed by the Medical Monitor. There are no blinding 1383 
procedures to be addressed in this feasibility study.  1384 
ï‚§ Adverse events attributable to study device (including DKA or seizure)  1385 
ï‚§ Two patients with â‰¥1 episode of severe hypoglycemia attributable to insulin delivered by 1386 
study device.  1387 
8.14 Sub-Group Analyses  1388 
Not applicable in this feasibility study.  1389 
8.15 Multiple Comparison/Multiplicity  1390 
Not applicable in this  single-arm feasibility study.  1391 
8.16 Exploratory Analyses  1392 
No additional exploratory analyses are planned.  1393 
8.17 Additional Tabulations and Analyses  1394 
Not applicable in this  single-arm feasibility study.  1395 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 57 OF 63 Chapter 9:  Data Collection and Monitoring  1396 
9.1 Case Report Forms and Other Data Collection  1397 
The main study data are collected on electronic case report forms ( eCRFs). When data are 1398 
directly collected in electronic case report forms, this will be considered the source data.  For any 1399 
data points for which the eCRF is not considered source (e.g. lab results that are transcribed from 1400 
a printed report into the eCRF), the original source documentation must be maintained in the 1401 
participantâ€™s  study chart or medical recor d. This source must be readily verifiable against the 1402 
values entered into eCRF.  Even where all study data are directly entered into the eCRFs at office 1403 
visits, evidence of interaction with a live subject must be recorded (e.g., office note, visit record, 1404 
etc.)    1405 
Electronic device data files are obtained from the study software and individual hardware 1406 
components.  These electronic device files are considered the primary source documentation.  1407 
9.2 Study Records Retention  1408 
Each participating site will maintain appr opriate medical and research records for this trial, in 1409 
compliance with ICH E6 and regulatory and institutional requirements for the protection of 1410 
confidentiality of participants.   1411 
Study documents should be retained for a minimum of 3 years after final reporting. These 1412 
documents should be retained for a longer period, however, if required by local regulations.  No 1413 
records will be destroyed without the written consent of the sponsor, if applicable.  It is the 1414 
responsibility of the sponsor to inform the investigator when these documents no longer need to 1415 
be retained.  1416 
9.3 Quality Assurance and Monitoring  1417 
Designated personnel from Emory University  will be responsible for maintaining quality 1418 
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 1419 
conducted and data are generated, documented and reported in compliance with the protocol, 1420 
Good Clinical Practice (GCP) and the applicable regulatory requirements, as well as to ensure 1421 
that the rights and wellbeing of trial participants are protected and that the reported trial data are 1422 
accurate, complete, and verifiable .  Adverse events will be prioritized for monitoring.  1423 
A risk-based monitoring (RBM) plan will be developed and revised as needed during the course 1424 
of the study, consistent with the FDA â€œGuidance for Industry Oversight of Clinical 1425 
Investigations â€” A Risk-Based Approach to Monitoringâ€ (August 2013).  Study conduct and 1426 
monitoring will conform with 21 Code of Federal Regulations (CFR) 812.  This plan describes in 1427 
detail who will conduct the monitoring, at what frequency monitoring will be done, at what level 1428 
of detail monitoring will be performed, and the distribution of monitoring reports.  1429 
The data of most importance for monitoring at the site are participant eligibility and adverse 1430 
events. Therefore, the RBM plan will focus on these areas.  As much as possible, remote 1431 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 58 OF 63 monitoring will be performed in real -time with on -site monitoring performed to evaluate the 1432 
verity and completeness of the key site data.  Elements of the RBM may include:  1433 
â€¢ Qualification assessment, training, and certification for sites and site personnel 1434 
â€¢ Oversight of Institutional Review Board (IRB) coverage and informed consent 1435 
procedures 1436 
â€¢ Central (remote) data monitoring: validation of data entry, data edits/audit trail, 1437 
protocol review of entered data and edits, statistical monitoring, study closeout  1438 
â€¢ On-site monitoring (site visits): source data verification, site visit report  1439 
â€¢ Agent/Device accountability  1440 
â€¢ Communications with site staff  1441 
â€¢ Patient retention and visit completion  1442 
â€¢ Quality control reports  1443 
â€¢ Management of noncompliance  1444 
â€¢ Documenting monitoring activities  1445 
â€¢ Adverse event reporting and monitoring 1446 
Coordinating Site (Emory University)  representatives or their designees may visit the study 1447 
facilities at any time in order to maintain current and personal knowledge of the study through 1448 
review of the records, comparison with source documents, observation and discussion of the 1449 
conduct and progress of the study.  The investigational site will provide direct access to all trial 1450 
related sites, source data/documents, and reports for the purpose of monitoring and auditing by 1451 
the sponsor, and inspection by local and regulatory authorities.  1452 
9.4 Protocol Deviations  1453 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1454 
requirements.  The noncompliance may be either on the part of the participant, the investigator, 1455 
or the study site staff. As a result of deviations, corrective actions are to be developed by the site 1456 
and implemented promptly.  1457 
The site PI/study staff is responsible for knowing and adhering to their IRB requirements.  1458 
Further details about the handling of protocol deviations will be included in the monitoring plan.  1459 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 59 OF 63 Chapter 10:  Ethics/Protection of Human Participants  1460 
10.1 Ethical Standard  1461 
The investigator will ensure that this study is conducted in full conformity with Regulations for 1462 
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 1463 
21 CFR Part 56, and/or the ICH E6.  1464 
10.2 Institutional Review Boards  1465 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 1466 
be submitted to the IRB for review and approval. Approval of both the protocol and the consent 1467 
form must be obtained before any participant is enrolled. Any amendment to the protocol will 1468 
require review and approval by the IRB before the changes are implemented to the study. All 1469 
changes to the consent form will be IRB approved; a determination will be made regarding 1470 
whether previously consented participants need to be re -consented. 1471 
10.3 Informed Consent Process  1472 
10.3.1 Consent Procedures and Documentation  1473 
Informed consent is a process that is initiated  prior to the individualâ€™s agreeing to participate in 1474 
the study and continues throughout the individualâ€™s study participation. Extensive discussion of 1475 
risks and possible benefits of participation will be provided to the participants and their families.  1476 
Consent forms will be IRB -approved and the participant will be asked to read and review the 1477 
document. The investigator will explain the research study to the participant and answer any 1478 
questions that may arise. All participants will receive a verbal explanat ion in terms suited to their 1479 
comprehension of the purposes, procedures, and potential risks of the study and of their rights as 1480 
research participants. Participants will have the opportunity to carefully review the written 1481 
consent form and ask questions prior to signing.  1482 
The participants should have the opportunity to discuss the study with their surrogates or think 1483 
about it prior to agreeing to participate. The participant will sign the informed consent document 1484 
prior to any procedures being done specifically for the study. The participants may withdraw 1485 
consent at any time throughout the course of the trial. A copy of the informed consent document 1486 
will be given to the participants for their records. The rights and welfare of the participants will 1487 
be protected by emphasizing to them that the quality of their medical care will not be adversely 1488 
affected if they decline to participate in this study.  1489 
10.3.2 Participant and Data Confidentiality  1490 
Participant confidentiality is strictly held in trust by the participating investigators, their staff, 1491 
and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological 1492 
samples and genetic tests in addition to the clinical information relating to participants.  1493 
Therefore, the study protocol, documentation, data, and all other information generated will be 1494 
held in strict confidence. No information concerning the study or the data will be released to any 1495 
unauthorized third party without prior written approval of the sponsor.  1496 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 60 OF 63 The study monitor, other authorized representatives of the sponsor, representatives of the IRB , 1497 
regulatory agencies  or company supplying study product may inspect all documents and records 1498 
required to be maintained by the investigator, including but not limited to, medical records 1499 
(office, clinic, or hospital) and pharmacy records for the participants in this study. The clinical 1500 
study site will permit access to such records.  1501 
The study participantâ€™s contact information will be securely stored at each clinical site for 1502 
internal use during the study. At the end of the study, all records will continue to be kept in a 1503 
secure location for as long a period as dictated by the reviewing IRB, institutional policies, or 1504 
sponsor requirements . 1505 
Study participant research data, which is for purposes of statistical analysis and scientific 1506 
reporting, will be transmitted to and stored at the Coordinating Site and Statistical Center. This 1507 
will not include the participantâ€™s contact or identifying information, unless otherwise specified in 1508 
the informed consent form . Rather, individual participants and their research data will be 1509 
identified by a unique study identification number. The study data entry and study management 1510 
systems used by clinical sites will be secured and password protected. At the end of the study, all 1511 
study databases will be de -identified and archived. 1512 
10.3.3 Future Use of Stored Specimens  and Data 1513 
Biologic samples from participants will not be stored for the purposes of this study. Genetic 1514 
testing will not be performed as part of this study.  1515 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 61 OF 63 Chapter 11:  References  1516 
1. Pasquel FJ, Umpierrez GE. Individualizing Inpatient Diabetes Management During the 1517 
Coronavirus Disease 2019 Pandemic. J Diabetes Sci Technol. 2020;14(4):705-707. 1518 
2. Team CC -R. Preliminary Estimates of the Prevalence of Selected Underlying Health 1519 
Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12- 1520 
March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-386. 1521 
3. Killerby ME, Link -Gelles R, Haight SC, et al. Characteristics Associated with 1522 
Hospitalization Among Patients with COVID -19 - Metropolitan Atlanta, Georg ia, March - 1523 
April 2020. MMWR Morb Mortal Wkly Rep. 2020;69(25):790-794. 1524 
4. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and Clinical Outcomes of 1525 
Adult Patients Hospitalized with COVID -19 - Georgia, March 2020. MMWR Morb 1526 
Mortal Wkly Rep. 2020;69(18):545-550. 1527 
5. Auld S, Caridi -Scheible M, Blum JM, et al. ICU and ventilator mortality among critically 1528 
ill adults with COVID -19. medRxiv. 2020. 1529 
6. Bally L, Thabit H, Hartnell S, et al. Closed -Loop Insulin Delivery for Glycemic Control 1530 
in Noncriti cal Care. N Engl J Med. 2018;379(6):547-556. 1531 
7. Boughton CK, Bally L, Martignoni F, et al. Fully closed- loop insulin delivery in 1532 
inpatients receiving nutritional support: a two- centre, open -label, randomised controlled 1533 
trial. Lancet Diabetes Endocrinol. 2019;7(5):368-377. 1534 
8. Thabit H, Hartnell S, Allen JM, et al. Closed -loop insulin delivery in inpatients with type 1535 
2 diabetes: a randomised, parallel -group trial. Lancet Diabetes Endocrinol. 1536 
2017;5(2):117-124. 1537 
9. Vanhorebeek I, Van den Berghe G. Hormonal and metabolic strategies to attenuate 1538 
catabolism in critically ill patients. Curr Opin Pharmacol. 2004;4(6):621-628. 1539 
10. Van den Berghe G. How does blood glucose control with insulin save lives in intensive 1540 
care? J Clin Invest. 2004;114(9):1187-1195. 1541 
11. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically 1542 
ill patients. N Engl J Med. 2001;345(19):1359-1367. 1543 
12. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin 1544 
therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med. 1545 
2003;31(2):359-366. 1546 
13. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in 1547 
critically ill patients. N Engl J Med. 2009;360(13):1283-1297. 1548 
14. Investigators N -SS, Finfer S, Liu B, et al. Hypoglycemia and risk of death in critically ill 1549 
patients. N Engl J Med. 2012;367(12):1108-1118. 1550 
15. Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, Wilson DM. 1551 
Association of hypoglycemia, hyperglycemia, and glucose variabil ity with morbidity and 1552 
death in the pediatric intensive care unit. Pediatrics. 2006;118(1):173-179. 1553 
16. Kulkarni H, Bihari S, Prakash S, et al. Independent Association of Glucose Variability 1554 
With Hospital Mortality in Adult Intensive Care Patients: Results  From the Australia and 1555 
New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation 1556 
Binational Registry. Crit Care Explor. 2019;1(8):e0025. 1557 
17. Chao WC, Tseng CH, Wu CL, Shih SJ, Yi CY, Chan MC. Higher glycemic variability 1558 
within the firs t day of ICU admission is associated with increased 30- day mortality in 1559 
ICU patients with sepsis. Ann Intensive Care. 2020;10(1):17. 1560 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 62 OF 63 18. Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in 1561 
Patients with COVID -19 and Pre -existing Type 2 Diabetes. Cell Metab. 1562 
2020;31(6):1068- 1077 e1063.  1563 
19. Sardu C, D'Onofrio N, Balestrieri ML, et al. Outcomes in Patients With Hyperglycemia 1564 
Affected by COVID -19: Can We Do More on Glycemic Control? Diabetes Care. 1565 
2020;43(7):1408-1415. 1566 
20. Pasquel FJ, Fayfman M, Umpierrez GE. Debate on Insulin vs Non- insulin Use in the 1567 
Hospital Setting -Is It Time to Revise the Guidelines for the Management of Inpatient 1568 
Diabetes? Curr Diab Rep. 2019;19(9):65. 1569 
21. Rayman G, Lumb AN, Kennon B, et al. Dexamethasone therapy in COVID -19 patients: 1570 
implications and guidance for the management of blood glucose in people with and 1571 
without diabetes. Diabetic Medicine. 2020;n/a(n/a). 1572 
22. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with 1573 
Covid-19 - Preliminary Report. N Engl J Med. 2020. 1574 
23. Davis GM, Galindo RJ, Migdal AL, Umpierrez GE. Diabetes Technology in the Inpatient 1575 
Setting for Management of Hyperglycemia. Endocrinol Metab Clin North Am. 1576 
2020;49(1):79-93. 1577 
24. Umpierrez GE, Klonoff DC. Diabetes Technology Update: Use of Insulin Pumps and 1578 
Continuous Glucose Monitoring in the Hospital. Diabetes Care. 2018;41(8):1579-1589. 1579 
25. Galindo RJ, Aleppo G, Klonoff DC, et al. Implementation of Continuous Glucose 1580 
Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring 1581 
During the COVID -19 Pandemic. J Diabetes Sci Technol. 2020;14(4):822-832. 1582 
26. Migdal AL, Spanakis EK, Galindo RJ, et al. Accuracy and Precision of Continuous 1583 
Glucose Monitoring in Hospitalized Patients Undergoing Radiology Procedures. J 1584 
Diabetes Sci Technol. 2020:1932296820930038. 1585 
27. Pasquel FJ, Lansang MC, Khowaja A, et al. A Randomized Controlled Trial Comparing 1586 
Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and 1587 
Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial. Diabetes Care. 1588 
2020;43(6):1242-1248. 1589 
28. Galindo RJ, Migdal AL, Davis GM, et al. Comparison of the FreeStyle Libre Pro Flash 1590 
Continuous Glucose Monitoring (CGM) System and Point -of-Care Capillary Glucose 1591 
Testing (POC) in Hospitalized Patients With Type 2 Diabetes (T2D) Treated With Basal - 1592 
Bolus Insulin Regimen. Diabetes Care. 2020. 1593 
29. Teles M, Sacchetta T, Matsumoto Y. COVID -19 Pandemic Triggers Telemedicine 1594 
Regulation and Intensifies Diabetes Management Techno logy Adoption in Brazil. J 1595 
Diabetes Sci Technol. 2020;14(4):797-798. 1596 
30. Shehav-Zaltzman G, Segal G, Konvalina N, Tirosh A. Remote Glucose Monitoring of 1597 
Hospitalized, Quarantined Patients With Diabetes and COVID -19. Diabetes Care. 1598 
2020;43(7):e75-e76. 1599 
31. Reutrakul S, Genco M, Salinas H, et al. Feasibility of Inpatient Continuous Glucose 1600 
Monitoring During the COVID -19 Pandemic: Early Experience. Diabetes Care. 2020. 1601 
32. Singh LG, Satyarengga M, Marcano I, et al. Reducing Inpatient Hypoglycemia in the 1602 
General Wards Using Real -Time Continuous Glucose Monitoring: The Glucose 1603 
Telemetry System, a Randomized Clinical Trial. Diabetes Care. 2020. 1604 
Automated I nsulin Delivery for INpatients with Dys Glycemia (AIDING) Feasibility Study  
 
VERSION  2.2 PAGE 63 OF 63 33. Fortmann AL, Spierling Bagsic SR, Talavera L, et al. Glucose as the Fifth Vital Sign: A 1605 
Randomized Controlled Trial of  Continuous Glucose Monitoring in a Non- ICU Hospital 1606 
Setting. Diabetes Care. 2020. 1607 
34. Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM. One Year Clinical 1608 
Experience of the First Commercial Hybrid Closed- Loop System. Diabetes Care. 1609 
2019;42(12):2190-2196. 1610 
35. Sherr JL, Buckingham BA, Forlenza GP, et al. Safety and Performance of the Omnipod 1611 
Hybrid Closed- Loop System in Adults, Adolescents, and Children with Type 1 Diabetes 1612 
Over 5 Days Under Free -Living Conditions. Diabetes Technol Ther. 2020;22(3):174-184. 1613 
36. Anderson SM, Buckingham BA, Breton MD, et al. Hybrid Closed- Loop Control Is Safe 1614 
and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for 1615 
Hypoglycemia. Diabetes Technol Ther. 2019;21(6):356-363. 1616 
37. Lawton J, Blackburn M, Rankin D, et al. Participants' Experiences of, and Views About, 1617 
Daytime Use of a Day -and-Night Hybrid Closed- Loop System in Real Life Settings: 1618 
Longitudinal Qualitative Study. Diabetes Technol Ther. 2019;21(3):119-127. 1619 
38. Buckingham B, Brown SA, Bode B, Levy C, GP F, Criego A. OmnipodÂ® 5 Automated 1620 
Glucose Control System, Powered by Horizonâ„¢. American Diabetes Association Annual 1621 
Scientific Meeting; June 12th, 2020, 2020; Chicago, Virtual.  1622 
39. Partridge H, Perkins B, Mathieu S, Nicholls A, Adeniji K. Clinical recommendations in 1623 
the management of the patient with type 1 diabetes on insulin pump therapy in the 1624 
perioperative period: a primer for the anaesthetist. Br J Anaesth. 2016;116(1):18-26. 1625 
40. Sobel SI, Augustine M, Donihi AC, Reider J, Forte P, Korytkowski M. Safety and 1626 
efficacy of a peri -operative protocol for patients with diabetes treated with continuous 1627 
subcutaneous insulin infusion who are admitted for same -day surgery. Endocr Pract. 1628 
2015;21(11):1269-1276. 1629 
41. Vanderhoek SM, Wolf RM. Use of continuous subcutaneous insulin infusion (CSII) 1630 
therapy in pediatric diabetes patients in the perioperative period. Paediatr Anaesth. 1631 
2019;29(9):901-906. 1632 
 1633 